#### Check for updates

#### **OPEN ACCESS**

EDITED BY Mohamed Rahouma, Weill Cornell Medical Center, NewYork-Presbyterian, United States

REVIEWED BY Vishal G. Shelat, Tan Tock Seng Hospital, Singapore Jinze Li, Sichuan University, China Massimo Baudo, Spedali Civili Brescia, Italy

\*CORRESPONDENCE Kuo Liang liangkuo611@xwh.ccmu.edu.cn

SPECIALTY SECTION This article was submitted to Surgical Oncology, a section of the journal Frontiers in Oncology

RECEIVED 03 July 2022 ACCEPTED 29 September 2022 PUBLISHED 18 October 2022

#### CITATION

Wang Z, Li S, Jia Y, Liu M, Yang K, Sui M, Liu D and Liang K (2022) Clinical prognosis of intraoperative blood salvage autotransfusion in liver transplantation for hepatocellular carcinoma: A systematic review and meta-analysis. *Front. Oncol.* 12:985281.

doi: 10.3389/fonc.2022.985281

#### COPYRIGHT

© 2022 Wang, Li, Jia, Liu, Yang, Sui, Liu and Liang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) The use, distribution or

reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Clinical prognosis of intraoperative blood salvage autotransfusion in liver transplantation for hepatocellular carcinoma: A systematic review and meta-analysis

Zheng Wang<sup>1</sup>, Saixin Li<sup>1</sup>, Yitong Jia<sup>2</sup>, Miao Liu<sup>2</sup>, Kun Yang<sup>3</sup>, Minghao Sui<sup>1</sup>, Dongbin Liu<sup>1</sup> and Kuo Liang<sup>1\*</sup>

<sup>1</sup>Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China, <sup>2</sup>Department of Anesthesiology, Xuanwu Hospital, Capital Medical University, Beijing, China, <sup>3</sup>Department of Evidence-Based Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China

**Background:** Intraoperative blood salvage autotransfusion(IBSA) has been widely used in a variety of surgeries, but the use of IBSA in hepatocellular carcinoma (HCC) patients undergoing liver transplantation (LT) is controversial. Numerous studies have reported that IBSA used during LT for HCC is not associated with adverse oncologic outcomes. This systematic review and meta-analysis aims to estimate the clinical prognosis of IBSA for patients with H+CC undergoing LT.

**Methods:** MEDLINE, Embase, Web of Science, and Cochrane Library were searched for articles describing IBSA in HCC patients undergoing LT from the date of inception until May 1, 2022, and a meta-analysis was performed. Study heterogeneity was assessed by  $l^2$  test. Publication bias was evaluated by funnel plots, Egger's and Begg's test.

**Results:** 12 studies enrolling a total of 2253 cases (1374 IBSA and 879 non-IBSA cases) are included in this meta-analysis. The recurrence rate(RR) at 5-year (OR=0.75; 95%Cl, 0.59-0.95; P=0.02) and 7-year(OR=0.65; 95%Cl, 0.55-0.97; P=0.03) in the IBSA group is slightly lower than non-IBSA group. There are no significant differences in the 1-year RR(OR=0.77; 95% Cl, 0.56-1.06; P=0.10), 3-years RR (OR=0.79; 95% Cl, 0.62-1.01; P=0.06),1-year overall survival outcome (OS) (OR=0.90; 95% Cl, 0.63-1.28; P=0.57), 3-year OS(OR=1.16; 95% Cl, 0.83-1.62; P=0.38), 5-year OS(OR=1.04; 95% Cl, 0.76-1.40; P=0.82),1-year disease-free survival rate(DFS) (OR=0.80; 95%Cl, 0.49-1.30; P=0.36), 3-year DFS (OR=0.99; 95%Cl, 0.64-1.55; P=0.98), and 5-year DFS(OR=0.88; 95%Cl, 0.60-1.28; P=0.50). Subgroup analysis shows a difference in the use of

leukocyte depletion filters group of 5-year RR(OR=0.73; 95%Cl, 0.55-0.96; P=0.03). No significant differences are found in other subgroups.

**Conclusions:** IBSA provides comparable survival outcomes relative to allogeneic blood transfusion and does not increase the tumor recurrence for HCC patients after LT.

**Systematic review registration:** https://www.crd.york.ac.uk/prospero/, identifier CRD42022295479.

KEYWORDS

hepatocellular carcinoma, intraoperative blood salvage autotransfusion, liver transplantation, leukocyte depletion filters, treatment outcome, meta-analysis.

# Introduction

Hepatocellular carcinoma (HCC) is the most frequent primary liver cancers, the sixth most common neoplasm, and the third most common cause of cancer death (1). Liver transplantation(LT) is the most curative treatment for HCC on cirrhosis in the absence of metastases and macroscopic vascular invasion, as it effectively treats both the tumor burden and the underlying liver disease. Milan criteria established LT as a valid treatment option for HCC patients with cirrhosis (2, 3). However, elevated portal pressure, increased collateral circulation and the hyperdynamic, dilated, thin-walled splanchnic circulation all contribute to an increased risk of hemorrhage during the LT which are distinct causes of bleeding that are different from those in other surgeries (4). Intraoperative hemorrhage has been recognized as a mortality risk, necessitating massive blood transfusions during LT (5).

Blood transfusion could be divided into autotransfusion and allogenic blood transfusion (ABT) based on the blood source. Three types of autologous transfusion exist: prestored autotransfusion, dilution autotransfusion, and intraoperative blood salvage autotransfusion(IBSA). ABT is the primary technique employed in conventional application, but it may transmit hepatitis virus and human immunodeficiency virus, as well as cause an immunological transfusion reaction (6, 7). Noninfectious risks are also well known, such as transfusionassociated circulatory overload and acute lung injury. In particular, ABT may impair the immune function of tumor patients (8), which could increase the risk of postoperative infections, lengthen hospital stays, and, in severe circumstances, even result in death (9). With the rising demand for clinical blood, the shortage of blood supply and the underlying risk of transfusion of banked blood, autologous blood transfusion is becoming more common in clinics to avoid or reduce the risks associated with ABT (10, 11).

The use of IBSA in HCC patients involving LT is controversial, the critical point is whether IBSA increases the risk of recurrence or metastasis due to reperfusion of tumor cells (12, 13). Even though this hypothesis is unwarranted, it still limits the utilization of IBSA. Foltys et al. have demonstrated IBSA does not modify the risk of HCC recurrence, the use of IBSA appears to be justified in highly selected HCC patients undergoing LT (14), and the European Society of Anesthesiology does not contraindicate its use in cancer patients (15), but there is still no consensus on its usage in patients undergoing LT for HCC (16). Since the published results were largely based on a retrospective analysis of cases from a single center, and randomized controlled trials (RCTs) are difficult to conduct in this setting, we conduct this meta-analysis to fully estimate the clinical prognosis of IBSA for patients with HCC undergoing LT which may be helpful in elucidating the issue.

## **Methods**

This systematic review and meta-analysis adhere to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (Supplementary Table 1) and has been registered with the International Prospective Register of Systematic Review (PROSPERO) database (registration number CRD42022295479) (17). This systematic review is conducted using the methodological guidance in the Cochrane Handbook for Systematic Reviews of Interventions (18). Any modifications to this protocol made over the

Abbreviations: ABT, allogenic blood transfusion; CI, confidence interval; DFS, disease-free survival rate; HCC, hepatocellular carcinoma; IBSA, intraoperative blood salvage autotransfusion; LDFs, leukocyte depletion filters; LT, liver transplantation; OR, odds ratio; OS, overall survival outcome; PROSPERO, International Prospective Register of Systematic Review; RCTs, randomized controlled trials; RR, the recurrence rate.

course of the study will be reported in PROSPERO and the final manuscript.

## Study identification and selection

The search strategies were created by an investigator (KY) with database search experience. We conducted database searches in the following databases: Medline (via PubMed), Web of Science databases, EMBASE and The Cochrane Library. Databases were used to identify suitable studies that were published up to 1 May 2022. Three search themes were combined with the Boolean operator 'and' in searching databases, and the search terms were as follows: 'Autotransfusion', 'Liver Transplantation' and 'Hepatocellular Carcinoma'. Detailed search strategy was shown in Supplementary Methods. Only English-language publications with human subjects were included in the searches. The following inclusion criteria were used: (a) a study that investigated the clinical prognosis during LT for HCC patients; (b) randomized clinical trial, high-quality case-control study, cohort study; (c) adults (over the age of 18). The exclusion criteria were as follows: (a) comments, case reports, and letters to the editors; (b) duplicate reports; (c) systematic reviews or meta-analyses. Two reviewers(YJ and SL) independently screened the articles according to the inclusion criteria. In case of discrepancies, consistencies will be ensured by a third reviewer(ZW). If several studies present data from the same study population, or multiple publications from the same research series are published in chronological sequence, the study with the most direct interventions or the largest sample size was kept.

#### Data extraction and quality assessment

The following parameters were extracted from the full-text article: the name of the first author, periodical titles, country, publication year, type of study, characteristics of IBSA group and non-IBSA group (eg, age, sex, follow-up years, sample size, overall survival outcome, disease-free survival outcome, recurrence rate and any adverse events caused by the preventive interventions). Two reviewers(YJ and DL) extracted data from studies in accordance with the screening process, and any inconsistencies were resolved by a third reviewer(SL). In case of any ambiguity or insufficient information, wherever possible, authors of primary studies were contacted by either telephone, email or post to obtain missing data. We made a summary sheet containing all the data fore-mentioned. On the other hand, we assessed the quality of published literature by two independent reviewers (ZW and YJ). The risk of bias of RCTs was assessed with items in the Cochrane Collaboration's tool (19). Non-RCTs (observational cohort and case-control studies) were assessed with the Newcastle-Ottawa Scale (20). Studies were classified as poor quality if their quality scores fell below 7, which was the threshold for high quality studies.

#### Outcome measures

The primary outcome of this meta-analysis is the tumor-related recurrence rate of use IBSA during LT for HCC. The recurrence time points will be 1-year, 3-year, 5-year and 7-year after LT. Radiological data was used to determine whether HCC had recurred (21). Other survival outcomes, such as the overall survival and the disease-free survival, if available, would also be analyzed and reported.

## Statistical analysis

Meta-analyses were conducted when appropriate using Review Manager 5.4 and STATA 16.0 statistical software. For each outcome, odds ratio (OR) and corresponding 95% confidence intervals(CI) were used to measure the association for each study. We will apply mathematical operations to convert data that is presented in the literature as median and quartiles into mean and standard deviation format (22). Forest plots will be used to visualize pooled estimates and the extent of heterogeneity among studies. The I<sup>2</sup> statistic were used to assess statistical heterogeneity among the included studies (I<sup>2</sup> values of <40%, 40%-60%, 50%-90%, and 75%-100% represent mild, moderate, substantial and considerable heterogeneity, respectively) (23).  $I^2 > 50\%$  will be considered as having a substantial heterogeneity, the random-effects model (the DerSimonian and Laird method) will be used to analyze the outcomes, otherwise, a fixed-effect model(the Mantei-Haenszle method) would be applied. The sources of heterogeneity will be explored by using sensitivity analyses. A subgroup analysis will be conducted to determine whether the results differed according to the use of leukocyte depletion filters (LDFs). The potential for publication bias will be assessed by the funnel plot, Egger test and Begg's test (24-26).

# Results

The database searches returned 123 results, 22 of which were excluded due to duplication. Further, 34 studies were excluded because they were reviews or qualitative study or were not relevant to the topic being studied. The remaining articles were fully read. Finally, 12 studies enrolling a total of 2253 cases (1374 IBSA cases and 879 non-IBSA cases) were included in the meta-analysis (14, 27–37). The process used for article selection is presented in Figure 1.

The selected studies had been published between 2005 and 2022. The sample size of studies ranged from 23 to 397. All of the studies were cohort studies. There were no randomized controlled trials. According to the Newcastle-Ottawa Scale, most (n = 11, 91.67%) of the studies were defined as high-quality studies (score more than 7), the detailed assessments are shown in Supplement Table 2. The baseline characteristics of the included studies are presented in Table 1.



#### TABLE 1 Characteristics of included studies.

Study	Year	Study type	LDFs used	>Sample size		Age ( yea	r, Mean ±SD)	Se	x, male	Outcome	NOS
				IBSA group	Non- IBSA group	IBSA group	Non-IBSA group	IBSA group	Non-IBSA group		score
Akbulut (27)	2013	RCS	0	24	59	52.0±1.8	51.0±1.2	22	52	RR,OS,DFS	7
Araujo (28)	2016	RCS	1	122	36	57.9±2.1*	61.8±1.4*	95	27	RR,OS	8
Foltys (14)	2011	RCS	1	40	96	54.9±6.6*	59.8±7.6*	28	74	RR,OS	7
Han (29)	2016	RCS	1	283	114	31.9±11.2	30.7±1.3	197	77	RR	9
Ivanics (30)	2021	RCS	0	76	34	56.0±1.9*	54.7±2.6*	61	30	RR,OS	8
Kim (31)	2012	RCS	1	121	109	52.3±7.1	52.6±7.5	97	86	RR	8
Kwon (32)	2021	RCS	1	220	129	54.0±1.6*	53.0±1.7*	192	121	RR,OS	8
Muscari (33)	2005	RCS	1	31	16	53.0±12.0	58.0±6.0	26	14	RR	7
Nutu (34)	2021	RCS	0	192	186	59.2±7.3	58.4±7.7	NA	NA	RR,OS,DFS	8
Pinto (35)	2021	RCS	0	122	34	59.0±7.0	60.0±6.0	75	20	RR,OS,DFS	7
Sutton (36)	2021	RCS	0	131	55	59.0±1.4*	61.8±1.3*	98	45	RR,OS	7
Weller	2021	RCS	0	12	11	54.8±6.7	58.3±7.4	9	9	RR	6

0, don't use LDFs; 1, use LDFs; DFS, Disease-free survival; IBSA, intraoperative blood salvage autotransfusion; NOS, Newcastle-Ottawa Scale; OS, Overall survival; RR, recurrence rate; RCS, retrospective cohort study; SD, standard deviations. \*Switched to mean ± SD according to the formula of Cochrane handbook.

## Primary outcomes: Tumor recurrence

Twelve studies reported the recurrence rate(RR) outcomes of IBSA and non-IBSA patients. Of them, seven studies provided a specified description of criteria for determining the recurrence and follow-up methods (14, 27, 29, 32, 35–37). The meta-

analysis data is displayed in Figure 2, the RR at 5-year (OR=0.75; 95%CI, 0.59-0.95; P=0.02) and 7-year(OR=0.65; 95%CI, 0.44-0.95; P=0.03) in the IBSA group was slightly lower than non-IBSA group. There were no significant differences in the 1-, and 3-years RR. The RR at 1-, and 3-year had ORs of 0.77 (95% CI, 0.56-1.06; P=0.10), and 0.79 (95% CI,



05

0.62-1.01; P=.06), respectively. No heterogeneity was found in 1year RR ( $I^2 = 0\%$ ), 3-year RR ( $I^2 = 0\%$ ), 5-year RR ( $I^2 = 0\%$ ), and 7-year RR( $I^2 = 0\%$ ), the fixed effect model was adopted.

## Overall survival and disease-free survival

Eight studies reported the overall survival(OS) outcomes of IBSA and non-IBSA patients (Figure 3). The overall survival outcomes at 1-, 3-, and 5-year were not significantly different. The OS at 1, 3, and 5-year had RRs of 0.90 (95% CI, 0.63-1.28; P=0.57), 1.16 (95% CI, 0.83-1.62; P=0.38), and 1.04 (95% CI, 0.76-1.40; P=0.82). Mild heterogeneity was observed in 1-year OS ( $I^2 = 0\%$ ), 3-year OS ( $I^2 = 29\%$ ), 5-year OS ( $I^2 = 28\%$ ). For all included studies performed in statistics of disease-free survival (DFS), there were no significant differences at 1-year DFS (OR=0.80; 95%CI, 0.49-1.30; P=0.36), 3-year DFS(OR=0.99; 95%CI, 0.64-1.55; P=0.98), 5-year DFS(OR=0.88; 95%CI, 0.60-1.28; P=0.50) (Figure 4). Mild heterogeneity was found in 1-year DFS ( $I^2 = 0\%$ ), 3-year DFS ( $I^2 = 20\%$ ), and 5-year DFS ( $I^2 = 0\%$ ).

## Subgroup analysis

A predesigned subgroup analysis was conducted according to the use of LDFs. Six studies attached LDFs to IBSA during LT (14, 28, 29, 31–33). The RR and OS outcomes were evaluated according to the use of LDFs, DFS was not evaluated due to lack of data. We observed a difference in the LDFs-using group of 5year RR (OR=0.73; 95%CI, 0.55-0.96; P=0.03). No significant differences were found in other subgroups. Pooled ORs are detailed in Figures 5, 6.

## Sensitivity analysis

For primary outcomes, pooled effects of ORs remained stable after removing any single study at 1-, 3-, 5-, and 7-year RR. For secondary outcomes, the removal of Kwon's study led to a reduction in heterogeneity at 3-year and 5-year OS (32). Filled pooled effects were adjusted for 3-year OS(OR=0.95; 95%CI,





0.70-1.29; P=0.73), 5-year OS(OR=0.86; 95%CI, 0.65-1.14; P=0.30), which were consistent with the initial meta-analysis. For 1-year OS, OR did not change much by removing either study (Supplementary Figure 1). Sensitivity analysis was not performed for DFS due to fewer studies.

## **Publication bias**

We used Egger's test and Begg's test to evaluate the publication bias for RR and OS outcomes. No indication of publication bias was observed for 1-year RR (Egger's test, P = 0.158; Begg's test, P = 0.7205), 3-year RR (Egger's test, P = 0.694; Begg's test, P = 0.4743), 5-year RR (Egger's test, P = 0.901; Begg's test, P = 0.0763), and for 1year OS (Egger's test, P = 0.943; Begg's test, P = 0.8065), 3-year OS (Egger's test, P = 0.943; Begg's test, P = 0.7639), 5-year OS (Egger's test, P = 0.517; Begg's test, P = 0.7639). Funnel plots were visually examined for symmetry for all outcomes reported (Supplementary Figures 2, 3).

# Discussion

In this comprehensive systematic review and meta-analysis, we identified 12 cohort studies investigating the clinical prognosis of IBSA during LT for HCC. The recurrence rate was used as the primary outcome, and the overall survival and disease-free survival were used as the secondary outcomes. The analyses showed that the RR at 5- and 7-year in the IBSA group was slightly lower than non-IBSA group. No significant differences were found between the IBSA and non-IBSA groups in the 1-, and 3-year RR outcomes. For secondary outcomes, the OS outcomes at 1-, 3-, and 5-year and the DFS outcomes at 1-, 3-, and 5-year were not significantly different. Sensitivity analysis was carried out to evaluate whether the result is stable and reliable, adjusted effects did not fluctuate much by omitting each study. Given the above, though no randomized studies were included, results of the meta-analysis could be considered relatively solid and trustworthy based on the current studies.

The use of IBSA reduces the requirement for allogeneic blood during surgery, preventing adverse transfusion reactions without having a negative impact on other clinical outcomes. However, oncological surgery is still regarded as a relative contraindication to IBSA over concern of reinfusing tumor cells and thereby causing tumor dissemination (13, 38, 39). The presence of neoplastic cells in blood samples from an autotransfusion system in 1975 established a link between the usage of IBSA and the occurrence of metastasis, although there is no proof that these cells have the capacity to cause recurrence or metastasis (40). In our study, IBSA did not increase the tumor recurrence rate and had comparable survival outcomes with non-IBSA. Based on existing literature, the European Society of Anesthesiology does not contraindicate the use of IBSA in

1.1.1 LDFs	Litents I otal L	vents Total	Weight M-	H, Random, 95% CI	M-H, Random, 95% Cl
Araujo 2016 Foltys 2011	6 122	1 36	2.2%	1.81 [0.21, 15.55]	
Han2016	31 283	12 114	20.5%	1.05 [0.52, 2.12]	_ <b>_</b>
Kim2012 Kwon 2021	11 121 2 31	17 109 1 16	15.6%	0.54 [0.24, 1.21] 1.03 [0.09, 12.35]	
Muscari 2005 Subtotal (95% CI)	37 220 817	32 129 500	35.9% 80.2%	0.61 [0.36, 1.04] 0.83 [0.53, 1.30]	
Total events Heterogeneity: Tau <sup>2</sup> = Test for overall effect	91 = 0.07; Chi <sup>2</sup> = 6.42 :: Z = 0.80 (P = 0.4	66 , df = 5 (P = 2)	0.27); l <sup>2</sup> = 22	<b>:x</b>	
1.1.2 non-LDFs					
Nutu 2021	8 192	11 186	11.7%	0.69 [0.27, 1.76]	
Weller 2021	1 12	2 11	1.6%	0.41 [0.03, 5.28]	
Subtotal (95% CI) Total events	335 17	252 17	19.8%	0.70 [0.34, 1.44]	-
Heterogeneity: Tau <sup>2</sup> - Test for overall effect	= 0.00; Chi <sup>2</sup> = 0.24 :: Z = 0.96 (P = 0.3	, df = 2 (P = 4)	0.89); l <sup>2</sup> = 09	6	
Total (95% CI)	1152	752	100.0%	0.77 [0.56, 1.06]	•
Total events Heterogeneity: Tau <sup>2</sup> =	108 = 0.00; Chi <sup>2</sup> = 6.73	83 , df = 8 (P =	0.57); l <sup>2</sup> = 09	6	
Test for overall effect Test for subgroup dif	Z = 1.63 (P = 0.1) ferences: Chi <sup>2</sup> = 0.	0) 15, df = 1 (P	= 0.70), l <sup>2</sup> =	0%	Favours [experimental] Favours [control]
D	1954	1954		Odda Balla	
Study or Subgroup 1.2.1 LDFs	IBSA I Events Total E	vents Total	Weight M-	Odds Ratio H, Random, 95% Cl	0005 KATIO M-H, Random, 95% Cl
Araujo 2016 Foltys 2011	16 122	6 36	5.6%	0.75 [0.27, 2.10]	
Han2016	47 283	23 114	19.1%	0.79 [0.45, 1.37]	
Kim2012 Kwon 2021	20 121 68 220	23 109 49 129	13.3%	0.74 [0.38, 1.44] 0.73 [0.46, 1.15]	
Subtotal (95% CI) Total events	786 157	484	71.8%	0.76 [0.57, 1.02]	•
Heterogeneity: Tau <sup>2</sup> - Test for overall effect	= 0.00; Chi <sup>2</sup> = 0.24 :: Z = 1.84 (P = 0.0	, df = 4 (P = 7)	0.99); l <sup>2</sup> = 09	6	
1.2.2 non-LDFs				1 21 /0 42 2 40	
Ivanics2021	1 76	15 59	5.3% 0.7%	0.44 [0.03, 7.25]	
Nutu 2021 Sutton 2021	25 192 8 131	26 186	16.9%	0.92 [0.51, 1.66]	
Weller 2021 Subtotal (95% CI)	1 12	3 11	1.0%	0.24 [0.02, 2.78]	
Total events	42	50	2012/4	0.00 (0.94, 1.90)	Ţ
Heterogeneity: Tau <sup>2</sup> - Test for overall effect	= 0.00; Chi <sup>2</sup> = 1.92	, df = 4 (P =	0.75); l <sup>2</sup> = 09	6	
Total (95% CI)	1221	-, 829	100.0%	0.79 [0.62, 1.01]	•
Total (95% CI) Total events	1221 199	829 166	100.0%	0.79 [0.62, 1.01]	•
<b>Total (95% CI)</b> Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect	1221 199 = 0.00; Chi <sup>2</sup> = 2.34 :: Z = 1.90 (P = 0.0	829 166 , df = 9 (P = 6)	100.0% 0.98); i <sup>2</sup> = 09	0.79 [0.62, 1.01] 6	0.01 0.1 1 10 100 Favours (experimental) Favours (control)
<b>Total (95% CI)</b> Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Test for subgroup dif	1221 199 = 0.00; Chi <sup>2</sup> = 2.34 :: Z = 1.90 (P = 0.0 ferences: Chi <sup>2</sup> = 0.	829 166 , df = 9 (P = 6) 18, df = 1 (P	100.0% 0.98); l <sup>2</sup> = 09 = 0.67), l <sup>2</sup> =	0.79 [0.62, 1.01] 6 0%	0.01 0.1 1 10 100 Favours [experimental] Favours [control]
Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Test for subgroup dif	1221 199 = 0.00; Chi <sup>2</sup> = 2.34 :: Z = 1.90 (P = 0.0 ferences: Chi <sup>2</sup> = 0. IBSA I Events Total E	829 166 , df = 9 (P = 6) 18, df = 1 (P non-IBSA vents Total	100.0% 0.98); i <sup>2</sup> = 09 = 0.67), i <sup>2</sup> = Weight M-	0.79 [0.62, 1.01] 6 0% Odds Ratio H, Random, 95% CI	0.01 0.1 10 100 Favours [experimental] Favours [control] 000 Odds Ratio M-H, Random, 95% Cl
Total (95% Cl) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Test for subgroup dif C Study or Subgroup 1.3.1 LDFs Araujo 2016	1221 199 = 0.00; Chi <sup>2</sup> = 2.34 :: Z = 1.90 (P = 0.0 ferences: Chi <sup>2</sup> = 0. IBSA Events Total E	829 166 , df = 9 (P = 6) 18, df = 1 (P non-IBSA vents Total 8 36	100.0% 0.98); l <sup>2</sup> = 09 = 0.67), l <sup>2</sup> = <u>Weight M-</u> 6.7%	0.79 [0.62, 1.01] 6 0% Odds Ratio H, Random, 95% CI 0.69 [0.27, 1.72]	0.01 0.1 10 100 Favours [experimental] Favours [control] 100 Odds Ratio M-H, Random, 95% Cl
Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect Test for subgroup dif C Study or Subgroup 1.3.1 LDFs Araujo 2016 Foltys 2011 Foltys 2011	1221 199 = 0.00; Chi <sup>2</sup> = 2.34 :: Z = 1.90 (P = 0.0 ferences: Chi <sup>2</sup> = 0. IBSA Events Total E 20 122 6 40 57 202	829 166 6) 18, df = 9 (P = 6) 18, df = 1 (P 100n-IBSA vents Total 8 36 22 96 27 95	100.0% $(0.98); l^2 = 09$ $(0.67), l^2 =$ Weight M- (6.7); 5.83; (5.83); 5.83;	0.79 [0.62, 1.01] 6 0% Odds Ratio H, Random, 95% CI 0.69 [0.27, 1.72] 0.59 [0.22, 1.60] 0.81 [0.5 ]	Odds Ratio M-H, Random, 95% Cl
Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect Test for subgroup dif C Study or Subgroup 1.3.1 LDFs Arauja 2016 Foltys 2011 Han2016 Kim2012	1221 $199$ = 0.00; Chi <sup>2</sup> = 2.34 : Z = 1.90 (P = 0.0 ferences: Chi <sup>2</sup> = 0.1 Events Total E 20 122 6 40 57 283 20 121	829 166 , df = 9 (P = 6) 18, df = 1 (P 18, df = 1 (P 18, df = 1 (P 18, df = 2 (P 8 36 22 96 27 114 25 109	100.0% 0.98); i <sup>2</sup> = 09 = 0.67), i <sup>2</sup> = <u>Weight M-</u> 6.7% 5.8% 20.9% 13.2%	0.79 [0.62, 1.01] 6 0% Odds Ratio H, Random, 95% CI 0.69 [0.27, 1.72] 0.59 [0.22, 1.60] 0.81 [0.48, 1.37] 0.67 [0.35, 1.28]	Odds Ratio M-H, Random, 95% Cl
Total (95% Cl) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect Test for subgroup dif C Study or Subgroup 1.3.1 LDFs Araujo 2016 Foltys 2011 Han2016 Kim2012 Kwon 2021 Subtotal (95% Cl)	I221           199           0.00; Chi² = 2.34           190 (P = 0.0)           ferences: Chi² = 0.           IBSA           Events           20           1221           199           100           ferences: Chi² = 0.           20           122           6           40           57           20           121           72           20           122           6           0           121           72           20           122           6           122           120           121           72           20           121           72           200           121           72           200           121           72           120           121           786	829 166 , df = 9 (P = 6) 18, df = 1 (P 18, df = 1 (P 18, df = 1 (P 18, df = 2 18, df = 2 18, df = 1 (P 10, 10, 10, 10, 10, 10, 10, 10, 10, 10,	100.0% 0.98); i <sup>2</sup> = 09 = 0.67), i <sup>2</sup> = Weight M- 6.7% 5.8% 20.9% 13.2% 27.8% 74.3%	0.79 [0.62, 1.01] 6 Odds Ratio H, Random, 95% CI 0.69 [0.27, 1.72] 0.59 [0.22, 1.60] 0.51 [0.48, 1.37] 0.67 [0.35, 1.28] 0.74 [0.47, 1.17] 0.73 [0.55, 0.96]	Odds Ratio M-H, Random, 95% Cl
Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect Test for overall effect Test for subgroup diff 1.3.1 LDFs Araujo 2016 Foltys 2011 Han2016 Kim2012 Kwon 2021 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Test for events!	1221 199 - 0.00; Chi <sup>2</sup> = 2.34 2 = 1.90 (P = 0.0 ferences: Chi <sup>2</sup> = 0. 185A P Events Total E 20 122 6 40 57 283 20 121 72 220 786 175 = 0.00; Chi <sup>2</sup> = 0.43 275	829 166 , df = 9 (P = 6) 18, df = 1 (P non-IBSA vents Total 8 36 22 96 27 114 25 109 51 129 484 133 , df = 4 (P = 3)	100.0% 0.98); l <sup>2</sup> = 09 = 0.67), l <sup>2</sup> = Weight M- 6.7% 5.8% 20.9% 13.2% 27.8% 74.3% 0.98); l <sup>2</sup> = 09	0.79 [0.62, 1.01] 6 Otds Ratio H, Random 95% CI 0.69 [0.27, 1.72] 0.59 [0.22, 1.60] 0.61 [0.44, 1.37] 0.67 [0.35, 1.28] 0.74 [0.47, 1.72] 0.73 [0.55, 0.96] 6	Odds Ratio M-H, Random, 95% Cl
Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect Test for overall effect Test for subgroup diff C Study or Subgroup 1.3.1 LDFs Araujo 2016 Foltys 2011 Han2016 Kim2012 Kwon 2021 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect 1.3.2 non-LDFs	1221           199           0.00; Ch <sup>2</sup> = 2.34           z = 0.00; Ch <sup>2</sup> = 0.0           ferences: Ch <sup>12</sup> = 0.           IBSA <b>Events Total E</b> 20         122           6         40           57         283           20         121           726         786           175         = 0.43; z = 2.24 (P = 0.0)	829 166 , df = 9 (P = 6) 18, df = 1 (P 18, df = 1 (P 18, df = 1 (P 18, df = 1 (P 122 96 22 96 22 96 22 96 22 96 23 129 484 133 , df = 4 (P = 3)	100.0% 0.98); l <sup>2</sup> = 09 = 0.67), l <sup>2</sup> = Weight M- 6.7% 5.8% 20.9% 27.8% 74.3% 0.98); l <sup>2</sup> = 09	0.79 [0.62, 1.01] 6 Odds Ratio H, Random 555 CI 0.69 [0.27, 1.72] 0.59 [0.22, 1.60] 0.61 [0.48, 1.37] 0.67 [0.35, 1.28] 0.74 [0.47, 1.74] 0.73 [0.55, 0.96] 6	0.01 0.1 10 100 Favours [experimental] Favours [control] 100 Odds Ratio M-H, Random, 95% Cl
Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect Test for overall effect Test for subgroup dif <u>1.3.1 LDFs</u> Araujo 2016 Foltys 2011 Han2016 Kim2012 Kim2012 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect 1.3.2 non-LDFs Ivanics2021	121 199 100; Chi <sup>2</sup> = 2.34 2.2 = 1.90 (P = 0.0 ferences: Chi <sup>2</sup> = 0. 105A 20 122 6 40 57 283 20 122 766 175 = 0.00; Chi <sup>2</sup> = 0.43 2 z = 2.24 (P = 0.0 1 75 = 0.00; Chi <sup>2</sup> = 0.43 2 z = 2.24 (P = 0.0	829 166 , df = 9 (P = 6) 18, df = 1 (P 18, df = 1 (P 18, df = 1 (P 18, df = 4 (P = 3) , df = 4 (P = 3) 1 34 1 34 1 34	100.0% 0.98); l <sup>2</sup> = 09 = 0.67); l <sup>2</sup> = Weight M- 6.7% 5.8% 20.9% 27.8% 74.3% 0.98); l <sup>2</sup> = 09 0.7%	0.79 [0.62, 1.01] 6 Ox Odds Ratio H, Random, 95% CI 0.69 [0.27, 1.72] 0.59 [0.22, 1.60] 0.61 [0.44, 1.37] 0.67 [0.35, 1.28] 0.74 [0.73, 1.28] 0.73 [0.55, 0.96] 6 0.44 [0.03, 7.25]	Odds Ratio M-H, Random, 95% CI
Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect Test for overall effect Test for subgroup dif <u>C</u> <u>Study or Subgroup</u> <u>1.3.1 LDFs</u> Araujo 2016 Foltys 2011 Han2016 Kim2012 Kim2012 Kim2012 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>3</sup> - Test for overall effect <u>1.3.2 non-LDFs</u> Ivanics2021 Nutu 2021 Sutto 2021	I221           199           0.00; Chi <sup>2</sup> = 2.34           z Z = 1.90 (P = 0.0           Terences: Chi <sup>2</sup> = 0.1           Events Total E           20         122           6         400; ST           20         122           6         400; ST           20         122           6         400; ST           20         121           72         200           1775         283           20.00; Chi <sup>2</sup> = 0.43         2.24 (P = 0.0           1         76           31         192           8         131	829 166 9 (P = 6) 18, df = 1 (P 18, df = 1 (P 18, df = 1 (P 18, df = 1 (P 13, df = 4 (P = 3) 1 34 32 186 5 55	100.0% 0.98); 1 <sup>2</sup> = 09 = 0.57), 1 <sup>2</sup> = 09 6.7% 5.0% 20.9% 13.2% 27.8% 74.3% 0.98); 1 <sup>2</sup> = 09 0.7% 19.3%	0.79 [0.62, 1.01] 6 Ox Odds Ratio H, Random, 95% CI 0.69 [0.27, 1.72] 0.59 [0.22, 1.60] 0.59 [0.44, 1.37] 0.57 [0.45, 1.37] 0.74 [0.45, 1.37] 0.74 [0.47, 1.17] 0.73 [0.55, 0.56] 6 0.44 [0.03, 7,25] 0.54 [0.54] 0.54 [0.52, 0.28]	Odds Ratio M-H, Random, 95% Cl
Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect Test for subgroup dif C Study or Subgroup 1.3.1 LDFs Araujo 2016 Folitys 2011 Han2016 Kim 2021 Kwon 2021 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> + Test for overall effect 1.3.2 non-LDFs Ivanics2021 Nutu 2021 Suttot 2021 Suttot 2021 Subtotal (95% CI)	$\begin{array}{c} 199 \\ 199 \\ 0.00; C^{10} = 2.34 \\ 2 = 1.90 \ (P=0.0) \\ \hline \  \  \  \  \  \  \  \  \  \  \  \  \$	829           166         6           60         18, df = 1 (P           18, df = 1 (P         10           18, df = 1 (P         20           10, df = 22         96           27         114           25         109           133         .df = 4 (P = 3)           1         34           32         186           5         5           4         11           286	100.0% 0.98); 1 <sup>2</sup> = 09 = 0.57), 1 <sup>2</sup> = Weight M- 6.7% 5.6% 20.9% 13.2% 27.8% 74.3% 0.980; 1 <sup>2</sup> = 09 0.7% 19.3% 4.2% 1.5% 25.7%	0.79 [0.62, 1.01] 6 Ox Odds Ratio H, Random, 95% CI 0.69 [0.27, 1.72] 0.59 [0.22, 1.60] 0.59 [0.22, 1.60] 0.61 [0.48, 1.37] 0.67 [0.35, 2.16] 0.74 [0.47, 1.17] 0.73 [0.55, 0.96] 6 0.44 [0.03, 7.25] 0.93 [0.54, 1.59] 0.65 [0.02, 2.08] 0.65 [0.05, 2.17] 0.61 [0.51, 1.27] 0.61 [0.51, 1.27]	Old Old Ratio M-H, Random, 95% Cl
Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect Test for overall effect Test for overall offect 1.3.1 LDFs Araujo 2016 Foltys 2011 Han2016 Kim2012 Kim2012 Kim2012 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> + Test for overall effect 1.3.2 non-LDFs Ivanics2021 Nutu 2021 Suttot 2021 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> +	$\begin{array}{c} 1221\\ 199\\ 0.00; Chi^2 = 2.34\\ 2.2 = 1.90 \ (P=0.0\\ Ferences: Chi^2 = 0.3\\ 100; Chi^2 = 0.4\\ 100; Chi^2 = 1.27\\ 100; Chi^2 = 1.$	829           166           , off = 9 (P =           6)           18, df = 1 (P)           non-IBSA           vents           7           114           22           96           27           133           41           33           1           1           32           1           34           42           42           41           42           41           42           41           42           41           42           41	100.0% 0.98); l <sup>2</sup> = 03 = 0.67), l <sup>2</sup> = Weight M- 6.7% 5.8% 20.9% 27.8% 27.8% 0.98); l <sup>2</sup> = 03 0.7% 13.3% 4.2% 1.5% 2.5% 0.74); l <sup>2</sup> = 03	0.79 [0.62, 1.01] 6 Ox Odds Ratio H, Random, 95% CI 0.69 [0.27, 1.72] 0.59 [0.22, 1.60] 0.41 [0.43, 1.24] 0.41 [0.43, 1.24] 0.74 [0.47, 1.17] 0.73 [0.55, 0.56] 6 0.44 [0.03, 7.25] 6 0.44 [0.03, 7.25] 1.59] 0.56 [0.20, 2.47] 0.56 [0.20, 2.47] 0.53 [0.51, 1.29] 6	Odds Ratio M-H, Random, 95% CI
Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect Test for overall effect Test for overall effect <b>C</b> <u>Study or Subgroup</u> <u>1.3.1 LDFs</u> Araujo 2016 Foltys 2011 Han2016 Kim2012 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect <b>1.3.2 non-LDFs</b> Natics2021 Nutu 2021 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect Test for overall effect	$\begin{array}{c} 1 = 0.03 \ ( - $	829 166 67 18, df = 9 (P = 60 18, df = 1 (P 18, df = 1 (P 18, df = 1 (P 133 .df = 4 (P = 134 .df = 4 (P = 134 .df = 4 (P = 8) 770	<b>100.0%</b> $0.98); l^2 = 03$ $0.67), l^2 = 0$ <b>Weight M-</b> 6.7% 5.8% 20.9% 13.2% 27.8% 74.3% $0.98); l^2 = 03$ 0.7% 4.2% 1.5% 25.7% $0.74); l^2 = 03$ <b>100.0%</b>	0.79 [0.62, 1.01] Colds Ratio H, Random, 95% CI 0.69 [0.27, 1.72] 0.59 [0.22, 1.60] 0.69 [0.27, 1.72] 0.59 [0.22, 1.60] 0.61 [0.48, 1.37] 0.71 [0.35, 1.28] 0.71 [0.35, 1.28] 0.74 [0.47, 1.05] 0.74 [0.47, 1.05] 0.73 [0.55, 0.96] 4 0.75 [0.59, 0.94]	Odds Ratio M-H, Random, 95% CI
Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect Test for overall effect Test for subgroup dif <u>A:subjor of Subgroup</u> <u>1:3:1 LDFs</u> Araujo 2016 Foltys 2011 Han2016 Kim2012 Kim2012 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect <u>1:3:2 non-LDFs</u> Nunics2021 Nutics2021 Sutton 2021 Sutton 202	$\begin{array}{c} 121\\ 199\\ 0.00; Chi^2 = 2.34\\ z = 1.90 \ (P=0.0\\ ferences: Chi^2 = 0.\\ \hline Events Total E\\ 20 \ 122\\ 6 \ 40\\ 57 \ 283\\ 20 \ 121\\ 766\\ 175\\ = 0.00; Chi^2 = 0.43\\ 766\\ 175\\ = 0.00; Chi^2 = 0.43\\ 192\\ 8 \ 131\\ 2 \ 12\\ 192\\ 8 \ 131\\ 2 \ 12\\ 192\\ 8 \ 131\\ 2 \ 12\\ 1192\\ 4411\\ = 0.00; Chi^2 = 1.27\\ z = 0.88 \ (P=0.3)\\ 1197\\ $	829 166 6 18, df = 9 (P = 6) 18, df = 1 (P 18, df = 1 (P 18, df = 1 (P 133 .df = 4 (P = 3) 1 34 32 186 5 55 4 21 42 26 .df = 4 (P = 3) 1 34 .df = 4 (P = 3) 7700 1770 7700 177	100.0% 0.98); l <sup>2</sup> = 03 = 0.67), l <sup>2</sup> = Weight M- 6.7% 5.8% 20.9% 13.2% 27.8% 74.3% 0.98); l <sup>2</sup> = 03 0.98); l <sup>2</sup> = 03 0.98); l <sup>2</sup> = 03 0.98); l <sup>2</sup> = 03 0.98); l <sup>2</sup> = 03 0.7% 19.3% 4.2% 4.2% 0.7% 0.7% 0.98); l <sup>2</sup> = 03 0.7% 0.98); l <sup>2</sup> = 03 0.7% 0.98); l <sup>2</sup> = 03 0.9% 0	0.79 [0.62, 1.01] 6 Oxi Odds Ratio H, Random, 95% CI 0.69 [0.27, 1.72] 0.59 [0.22, 1.60] 0.61 [0.44, 1.37] 0.67 [0.25, 1.28] 0.41 [0.03, 7.25] 0.73 [0.55, 0.96] 6 0.44 [0.03, 7.25] 0.55 [0.50, 2.08] 6 0.75 [0.55, 0.95] 7	Odds Ratio M-H, Random, 95% CI
Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect Test for overall effect Test for overall of the Araujo 2016 Foltys 2011 Han2016 Kim2012 Kwon 2021 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> a Test for overall effect Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> a Test for overall effect Total events	$\begin{array}{c} 121\\ 199\\ 0.00; Ch^2 = 2.34\\ 2.00; Ch^2 = 2.34\\ 2.2 - 1.90 (P = 0.0\\ ferences: Ch^2 = 0.0\\ \hline events Total E\\ 20 122\\ 6 40\\ 57 283\\ 20 121\\ 72 220\\ 786\\ 175\\ = 0.00; Ch^2 = 0.43\\ 2 12\\ 411\\ 2 12\\ 411\\ 2 12\\ 411\\ 2 12\\ 411\\ 42\\ = 0.00; Ch^2 = 1.84\\ 197\\ 217\\ = 0.00; Ch^2 = 1.84\\ 197\\ 1197\\ 217\\ = 0.00; Ch^2 = 1.84\\ 197\\ 1197\\ 217\\ = 0.00; Ch^2 = 1.84\\ 2 2 = 2.38 (P = 0.0\\ 197\\ 1197\\ 2 = 0.00; Ch^2 = 1.84\\ 2 = 2.38 (P = 0.0\\ 197\\ 197\\ 2 = 0.01; Ch^2 = 1.84\\ 2 = 2.38 (P = 0.0\\ 197\\ 197\\ 2 = 0.01; Ch^2 = 1.84\\ 2 = 2.38 (P = 0.0\\ 197\\ 197\\ 2 = 0.01; Ch^2 = 1.84\\ 2 = 2.38 (P = 0.0\\ 197\\ 197\\ 197\\ 2 = 0.01; Ch^2 = 1.84\\ 197\\ 197\\ 197\\ 197\\ 197\\ 197\\ 197\\ 197$	829           166	100.0% $0.98)$ ; $l^2 = 03$ $0.677$ , $l^2 =$ <b>Weight M</b> -           6,7%           5,8%           20.9%           13.2%           27.8%           0.98); $l^2 = 09$ 0.7%           19.3%           4.2%           1.5%           25.7%           0.74); $l^2 = 09$ 100.0%           0.99); $l^2 = 09$ 0.71), $l^2 = 07$	0.79 [0.62, 1.01] 6 0X Odds Ratio H, Random, 95X (1 0.69 [0.27, 1.72] 0.59 [0.22, 1.60] 0.61 [0.48, 1.37] 0.71 [0.35, 1.28] 0.61 [0.55, 0.96] 6 0.44 [0.03, 7.25] 0.39 [0.54, 1.59] 0.65 [0.20, 2.08] 0.35 [0.05, 0.95] 6 0,75 [0.59, 0.95] 6 05	Odds Ratio M-H, Random, 95% CI
Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect Test for overall effect Test for overall effect Test for overall effect Acaulo 2016 Foltys 2011 Han2016 Kim2012 Koron 2021 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> + Test for overall effect 1.3.2 non-LDFs Ivanics2021 Nutu 2021 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> + Test for overall effect Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> + Test for overall effect Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> + Test for overall effect Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> + Test for overall effect	121           199           0.00; Chi <sup>2</sup> = 2.34           2.2 = 1.90 (P = 0.0           Terences: Chi <sup>2</sup> = 0.3           Events Total E           20           122           6           20           6           20           122           6           20           122           6           20           122           6           20           122           6           20           122           6           20           122           6           20           121           72           200; Chi <sup>2</sup> = 0.43           1197           217           200; Chi <sup>2</sup> = 1.27           212           20, Chi <sup>2</sup> = 1.27           217           20, Chi <sup>2</sup> = 1.28           1197           217           20, Chi <sup>2</sup> = 1.28           217           20; Chi <sup>2</sup> = 1.27           217           210           211	829 166 6, df = 9 (P = 6) 18, df = 1 (P 18, df = 1 (P 18, df = 1 (P 8 36 22 96 27 114 23 129 5 4 133 1 34 32 186 5 55 4 11 226 4 12 2 18 5 5 4 11 2 26 5 7 7 7 7 7 7 7 7 7 7 7 7 7 7	<b>100.0%</b> <b>0.98</b> ); $l^2 = 03$ <b>0.67</b> ), $l^2 = 03$ <b>Weight M-</b> <b>5.9%</b> <b>20.9%</b> <b>13.2%</b> <b>27.3%</b> <b>0.98</b> ); $l^2 = 03$ <b>0.7%</b> <b>15.3%</b> <b>2.5%</b> <b>0.74</b> ; $l^2 = 03$ <b>100.0%</b> <b>0.99</b> ); $l^2 = 03$ <b>100.0%</b>	0.79 [0.62, 1.01] 6 0% Odds Ratio H, Random, 95% CI 0.59 [0.22, 1.60] 0.59 [0.22, 1.60] 0.59 [0.22, 1.60] 0.64 [0.48, 1.37] 0.67 [0.35, 0.96] 6 0.44 [0.03, 7.25] 0.73 [0.55, 0.96] 6 0.44 [0.03, 7.25] 0.73 [0.55, 0.96] 6 0.75 [0.59, 0.95] 6 0% Odds Ratio Market Ratio	0.01 0.1 10 100 Favours [experimental] Favours [control] 100 Odds Ratio M-H, Random, 95% Cl 0.01 0.1 0.1 10 100 Favours [experimental] Favours [control] 100
Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect Test for overall effect Test for overall effect Test for overall effect Particle 2016 Foliys 2011 Han2018 Kim2018 Ki	$\begin{array}{c} 121\\ 199\\ 0.00; Chi^3 = 2.34\\ 2.2 = 1.90 (P = 0.0\\ Ferences: Chi^3 = 0.1\\ Events: Total E \\ 20 & 122\\ 6 & 40\\ 57 & 283\\ 20 & 121\\ 72 & 220\\ 72 & 220\\ 72 & 220\\ 72 & 220\\ 72 & 220\\ 72 & 220\\ 72 & 220\\ 72 & 220\\ 72 & 220\\ 72 & 220\\ 72 & 220\\ 72 & 220\\ 72 & 220\\ 72 & 220\\ 72 & 220\\ 72 & 220\\ 72 & 220\\$	829           166           , off = 9 (P =           6)           18, off = 1 (P           non-IBSA           wents Total           8           62           96           27           114           25           454           133           1           30           1           34           32           1           44           33           1           34           32           134           32           1           44           36           5           4           45           46           47           20           770           175           .df = 1 (P           wonn-IBSA	100.0% 0.98); $l^2 = 03$ $= 0.67$ ), $l^2 = 03$ $\frac{8}{20.9\%}$ 13.2% 27.3% 0.98); $l^2 = 03$ 0.7% 19.3% 4.2% 1.5% 15.5% 15.5% 15.5% 0.74); $l^2 = 03$ 100.0% 0.99); $l^2 = 03$ $= 0.71$ ), $l^2 = 03$	0.79 [0.62, 1.01] 6 0% Odds Ratio H, Random, 95% CI 0.59 [0.22, 1.60] 0.59 [0.22, 1.60] 0.59 [0.22, 1.60] 0.67 [0.35, 1.60] 0.73 [0.44, 1.37] 0.73 [0.55, 0.96] 6 0.44 [0.03, 7.25] 0.73 [0.55, 0.96] 6 0.75 [0.59, 0.95] 6 0% Odds Ratio M, Random, 95% CI	0.01 0.1 10 100 Favours [experimental] Favours [control] 0dds Ratio M-H, Random, 95% Cl 0.01 0.1 10 100 Favours [experimental] Favours [control] 0dds Ratio M-H, Random, 95% Cl
Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Test for overall effect Test for overall effect Araujo 2016 Foltys 2011 Han2016 Kim2012 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Test for overall effect	$\begin{array}{c} 1 = 0.03 \ (b^{-} = 0.3) \\ 100 \ (b^{-} = 2.34 \\ 2.2 = 1.90 \ (b^{-} = 0.34 \\ 2.2 = 1.90 \ (b^{-} = 0.0 \\ 100 \ (b^{-} = 0.34 \\ 2.2 = 1.90 \ (b^{-} = 0.4 \\ 100 \ (b^{-} = 0.4 \\ 2.2 = 0.2 \\ 1.2 \\ 2.2 \\ 2.4 \ (b^{-} = 0.4 \\ 1.2 \\ 2.1 \\ 2.4 \\ 2.1 \\$	829           166           , df = 9 (P =           6)           18, df = 1 (P           wents Total           8           6           90           133           , df = 4 (P =           3)           1           14           32           464           133           , df = 4 (P =           3)           1           42           , df = 3 (P =           8)           770           125           12, df = 1 (P           wents Total           29           21, df = 1 (P           wents Total           29           27	<b>100.0%</b> <b>0.98</b> ); $l^2 = 03$ <b>0.98</b> ); $l^2 = 0.67$ ), $l^2 =$ <b>Weight M-</b> <b>6.7%</b> <b>5.8%</b> <b>20.5%</b> <b>74.3%</b> <b>74.3%</b> <b>0.98</b> ); $l^2 = 03$ <b>0.7%</b> <b>15.3%</b> <b>25.7%</b> <b>0.74</b> ); $l^2 = 03$ <b>100.0%</b> <b>0.71</b> ); $l^2 = 03$ <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0%</b> <b>100.0</b>	0.79 [0.62, 1.01] 6 OX Cdds Ratio H, Random, 95% CI 0.69 [0.27, 1.72] 0.59 [0.22, 1.60] 0.69 [0.27, 1.72] 0.59 [0.22, 1.60] 0.61 [0.48, 1.37] 0.73 [0.55, 0.96] 6 0.44 [0.03, 7.25] 0.74 [0.47, 1.81] 0.74 [0.47, 1.81] 0.74 [0.47, 1.81] 0.74 [0.47, 1.81] 0.74 [0.47, 1.81] 0.75 [0.59, 0.95] 6 OX Cdds Ratio H, Random, 95% CI 0.41 [0.15, 1.08] 6 0.41 [0.15, 1.08] 6 0.41 [0.15, 1.08] 6 0.41 [0.15, 1.08] 7 0.41 [0.15, 1.08] 0.41 [0.15, 1.08] 7 0.41 [0.15, 1.08] 7 0.41 [0.15, 1.08] 7 0.41 [0.15, 1.08] 7 0.41 [0.15, 1.08] 0.41	0.01 0.1 Favours [experimental] Favours [control] 0dds Ratio M-H, Random, 95% Cl 0.01 0.1 1 10 100 Favours [experimental] Favours [control]
Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Test for overall effect Test for overall effect 1.3.1 LDFs Araujo 2016 Foltys 2011 Han2016 Kim2012 Kwon 2021 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Test for overall effect Test for subgroup diff D Subocal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Test for subgroup diff D Subocal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for subgroup diff D Subgroup diff D Subgroup diff Total events Heterogeneity: Tau <sup>2</sup> - Test for subgroup diff D Subgroup diff D Tuble events Heterogeneity: Tau <sup>2</sup> - Test for subgroup diff D Subgroup diff D Tuble events Heterogeneity: Tau <sup>2</sup> - Test for subgroup diff D Test for subgroup diff D	$\begin{array}{c} 1 = 0.03, 0^{-} 0.03\\ 1 = 21\\ 1 = 0.00; Ch2 = 2.34\\ z = -1.90, 0^{-} = 0.0\\ \hline \text{ferences: Chl2} = 0.0\\ \hline \text{ferences: Chl2} = 0.0\\ \hline \text{ferences: Chl2} = 0.2\\ 2 & 122\\ 6 & 40\\ 57 & 283\\ 20 & 121\\ 72 & 220\\ 786\\ 175\\ z = 0.00; Chl2 = 0.43\\ z = 2.24 (P = 0.0\\ 1 & 76\\ 1 & 192\\ 8 & 131\\ 2 & 122\\ 411\\ 2 & 122\\ 411\\ 2 & 20\\ 1197\\ 2 & 20, 0.88 (P = 0.3\\ 1197\\ 2 & 20, 0.05 (Chl2 = 1.84\\ z = 2.38 (P = 0.0\\ 1197\\ 2 & 109\\ 1197\\$	829           166           , df = 9 (P =           6)           18, df = 1 (P           wents Total           8         36           22         96           27         114           25         109           133         .df = 4 (P =           3)         1           1         34           32         186           5         55           4         11           286         5           4         286           20         175           1, df = 3 (P =           2)         14, df = 1 (P           20         14, df = 1 (P           29         96           27         114, df = 1 (P           29         96           27         114, df = 1 (P           29         96           27         114           210         56	100.0% 0.98); $l^2 = 03$ $= 0.67$ ), $l^2 = 0$ $\frac{6}{5.7\%}$ $\frac{5}{5.8\%}$ 20.5% 13.2% 74.3% $0.98$ ); $l^2 = 09$ 0.7% 19.3% 4.2% 1.5% 25.7% $0.74$ ); $l^2 = 09$ 100.0% $0.99$ ); $l^2 = 09$ 100.0% $0.71$ ), $l^2 = 0$ 100.0%	0.79 [0.62, 1.01] Cotors and the second sec	0.01 0.1 Favours [experimental] Favours [control] 100 0dds Ratio M-H, Random, 95% CI
Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Test for overall effect Test for overall effect 1.3.1 LDFs Araujo 2016 Foltys 2011 Han2016 Kim2012 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Test for overall effect Test for overall effect Test for overall effect Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> -	$\begin{array}{c} 1 = 0.03, 0^{-} 0.03\\ \hline 1000 \ Chi^{2} = 2.34\\ c \ 2 = 0.00, Chi^{2} = 0.03\\ \hline events \ Total \ E \\ \hline events \ Total \ Chi^{2} = 0.03\\ \hline events \ Total \ E \\ \hline events \ Total \ E \\ \hline events \ Chi^{2} = 0.43\\ c \ 122\\ c \ 121\\ c \ 20\\ c \ 121\\ c \ 12$	$\begin{array}{c} 829\\ 166\\ (, df = 9 (P = 6)\\ 6)\\ 18, df = 1 (P)\\ 18, df = 4 (P = 3)\\ 27 114\\ 25 109\\ 11 14\\ 27 114\\ 25 166\\ 5 11 14\\ 27 114\\ 133\\ .df = 4 (P = 3)\\ 134\\ .df = 4 (P = 3)\\ 134\\ .df = 4 (P = 3)\\ 134\\ .df = 3 (P = 6)\\ 114\\ 29\\ .df = 3 (P = 6)\\ 114\\ 29\\ .df = 1 (P = 7)\\ 114\\ 29\\ .df = 1 (P = 7)\\ 114\\ 29\\ .df = 1 (P = 7)\\ .df = 1 ($	100.0% 0.98); l <sup>2</sup> = 03 = 0.67), l <sup>2</sup> = Weight M- 6.7% 5.5% 20.9% 74.3% 74.3% 0.98); l <sup>2</sup> = 09 0.7% 4.2% 1.5% 25.7% 0.74); l <sup>2</sup> = 09 100.0% 0.99); l <sup>2</sup> = 09 100.0% 0.99); l <sup>2</sup> = 03 100.0% 0.99); l <sup>2</sup> = 03 0.99); l <sup>2</sup> = 03 0.99; l <sup>2</sup> = 34 0.22; l <sup>2</sup> = 34 0.99; l <sup>2</sup> = 34 0.90; l <sup>2</sup> = 34 0; l <sup>2</sup> = 34	0.79 [0.62, 1.01] Colds Ratio H, Random, 95% CI 0.69 [0.27, 1.72] 0.59 [0.22, 1.60] 0.69 [0.27, 1.72] 0.59 [0.22, 1.60] 0.61 [0.48, 1.37] 0.67 [0.35, 1.28] 0.74 [0.47, 10.35, 1.28] 0.74 [0.47, 10.35, 1.28] 0.74 [0.47, 10.35, 1.28] 0.93 [0.54, 1.59] 0.65 [0.20, 2.08] 0.35 [0.05, 0.96] 4 0.41 [0.15, 1.08] 0.41 [0.15, 1.0	Odds Ratio M-H, Random, 95% Cl Golds Ratio
Total (95% CI) Total events Heterogeneity: Tau? Test for overall effect Test for overall effect Test for overall effect <b>C</b> <u>Study or Subgroup</u> J.3.1 LDFs Araujo 2016 Follys 2011 Han2016 Kim2012 Subtotal (95% CI) Total events Heterogeneity: Tau? Test for overall effect District events Heterogeneity: Tau? Test for overall effect Test for subgroup dif Subtotal (95% CI) Total events Heterogeneity: Tau? Test for overall effect Test for subgroup dif Study or Subgroup dif Subgroup dif Subgroup dif Subgroup dif Subgroup dif Subgroup dif Subgroup dif Subgroup dif Subgroup dif Subgroup dif Subgroup dif Subgroup dif Sub	$\begin{array}{c} 1 \\ 19 \\ 19 \\ 20 \\ 10 \\ 10 \\ 10 \\ 10 \\ 10 \\ 10 \\ 10$	$\begin{array}{c} 829\\ 166\\ (, df = 9 (P = 6)\\ 18, df = 1 (P)\\ 18, df = 4 (P = 3)\\ 11, 229\\ 133\\ .df = 4 (P = 3)\\ 134\\ .df = 4 (P = 3)\\ 134\\ .df = 4 (P = 10)\\ 135\\ .df = 3 (P = 6)\\ 175\\ .df = 8 (P = 2)\\ 14, df = 1 (P)\\ 14, df = 1 (P)\\ 14, df = 1 (P)\\ 14, df = 1 (P = 9)\\ 14, df = 1 (P = 10)\\ 14, $	$\begin{array}{r} \textbf{100.0\%} \\ \textbf{0.98}; \ l^2 = 0.9 \\ \textbf{0.67}, \ l^2 = \\ \textbf{Weight M-} \\ \textbf{5.5\%} \\ \textbf{5.5\%} \\ \textbf{20.9\%} \\ \textbf{74.3\%} \\ \textbf{75.6\%} \\ \textbf{25.7\%} \\ \textbf{0.98}; \ l^2 = 0.9 \\ \textbf{100.0\%} \\ \textbf{0.99}; \ l^2 = 0.9 \\ \textbf{100.0\%} \\ \textbf{0.99}; \ l^2 = 0.9 \\ \textbf{100.0\%} \\ \textbf{100.0\%} \\ \textbf{0.99}; \ l^2 = 0.9 \\ \textbf{100.0\%} \\ \textbf{100.0\%} \\ \textbf{0.92}; \ l^2 = 0.9 \\ \textbf{100.0\%} \\ \textbf{1000.0\%} \\ \textbf{1000.0\%}$	0.79 [0.62, 1.01] 6 0X Odds Ratio H, Random, 95X CI 0.69 [0.27, 1.72] 0.59 [0.22, 1.60] 0.69 [0.27, 1.72] 0.59 [0.22, 1.60] 0.61 [0.44, 1.37] 0.67 [0.35, 1.28] 0.67 [0.35, 0.36] 6 0.41 [0.03, 7.25] 0.65 [0.20, 2.08] 0.55 [0.59, 0.95] 6 0.75 [0.59, 0.95] 6 0X Odds Ratio H, Random, 95X CI 0.41 [0.15, 1.08] 0.41 [0.15, 1.08] 0.41 [0.15, 1.18] 0.41 [0.15, 1.18] 0.41 [0.15, 1.18] 0.45 [0.45, 1.37] 0.45 [0.45, 1.35] 0.45 [0.45, 1.35] 0.45 [0.45, 1.35] 0.45 [0.45, 1.35] 0.45 [0.45, 1.35] 0.45 [0.45, 1.35] 0.45 [0	0.01 0.1 10 100 Favours [experimental] Favours [control] 0dds Ratio M-H, Random, 95% CI 0.01 0.1 10 100 Favours [experimental] Favours [control] 0dds Ratio M-H, Random, 95% CI
Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect Test for overall effect Test for overall effect Test for overall effect Araujo 2016 Follys 2011 Han2016 Kim2012 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> a Test for overall effect 1.3.2 non-LDFs Numics2021 Weilfer 2021 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> a Test for overall effect Total events Heterogeneity: Tau <sup>2</sup> a Test for overall effect Total events Heterogeneity: Tau <sup>2</sup> a Test for overall effect Total events Heterogeneity: Tau <sup>2</sup> a Test for overall effect Test for subgroup dif D Study or Subgroup Follys 2011 Han2016 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> a Test for overall effect Test for subgroup dif Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> a Test for overall effect Follys 2011 Han2016 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> a Test for overall effect Follys 2011 Han2016 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> a Test for overall effect Follys 2011 Han2016 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> a Test for overall effect Follys 2011 Han2016 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> a Test for overall effect Follys 2011 Han2016 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> a Test for overall effect Follys 2011 Han2016 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> a Test for overall effect	$\begin{array}{c} 1 \\ 19 \\ 19 \\ 20 \\ 100 $	829           166           , df = 9 (P =           6)           18, df = 1 (P)           non-IBSA           wents Total           8         36           22         96           27         114           25         109           51         129           133         484           32         186           5         55           42         11           42         6f = 3 (P =           8)         7770           175         , df = 3 (P =           20         7700           175         , df = 1 (P)           vents Total         21           20         27           14, df = 1 (P)           21         29           20         51           21         21           21         21           21         21           21         21           21         37           21         37           21         37           21         37           31         37	100.0% 0.98); l <sup>2</sup> = 03 = 0.67), l <sup>2</sup> = Weight M- 6.7% 5.8% 20.9% 74.3% 74.3% 0.98); l <sup>2</sup> = 03 0.7% 19.3% 4.2% 1.5% 0.98); l <sup>2</sup> = 03 100.0% 0.99); l <sup>2</sup> = 03 0.99); l <sup>2</sup> = 03 0.900; l <sup>2</sup> = 03 0.200; l <sup>2</sup> = 34 8.800; l <sup>2</sup> = 34 0.900;	0.79 [0.62, 1.01] 6 0X Odds Ratio H, Random, 95X CI 0.59 [0.22, 1.60] 0.69 [0.27, 1.72] 0.59 [0.22, 1.60] 0.41 [0.44, 1.37] 0.67 [0.35, 1.28] 0.74 [0.47, 1.59] 0.73 [0.55, 0.96] 6 0.44 [0.03, 7.25] 0.53 [0.54, 1.59] 0.54 [0.51, 1.59] 0.55 [0.59, 0.95] 6 0X Odds Ratio H, Random, 95X CI 0.41 [0.15, 1.08] 0.41 [0.15, 1.08] 0.41 [0.15, 1.08] 0.41 [0.15, 1.08] 0.45 [0.35, 1.23] 0.55 [0.35, 1.23] 0.55 [0.35, 1.23]	Odds Ratio M-H, Random, 95% CI Odds Ratio M-H, Random, 95% CI Odds Ratio M-H, Random, 95% CI Odds Ratio M-H, Random, 95% CI Favours [experimental] Favours [control]
Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Test for overall effect Test for overall effect Araujo 2016 Folivs 2011 Han2016 Kim2012 Kurd 2021 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect 1.3.2 con-LDFs Natics 2021 Nutu 2021 Nutu 2021 Nutu 2021 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Test for overall effect Subtoal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Subtoal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect	$\begin{array}{c} 1 \\ 199 \\ 0 \\ 100$	829           166           , df = 9 (P =           6)           18, df = 1 (P           wents Total           8         36           22         96           27         114           133         44           133         44           134         134           134         134           134         132           134         44 (P =           134         132           134         132           134         44 (P =           137         44 (P =           137         14           138         44 (P =           175         , df = 1 (P           29         96           29         14, df = 1 (P =           99         99           14         210           56         1 (P =           99         91           334         55	100.0% 0.98); l <sup>2</sup> = 03 = 0.67), l <sup>2</sup> = Weight M- 5.5% 20.9% 27.9% 27.9% 27.9% 0.98); l <sup>2</sup> = 03 0.7% 13.3% 1.5% 1.5% 0.74); l <sup>2</sup> = 03 100.0% 0.99); l <sup>2</sup> = 03 100.0% 0.99); l <sup>2</sup> = 03 100.0% 15.6% 72.9% 0.22); l <sup>2</sup> = 34 8.8% 14.3%	0.79 [0.62, 1.01] 6 0% Odds Ratio H, Random, 95% CI 0.69 [0.27, 1.72] 0.59 [0.22, 1.60] 0.59 [0.22, 1.60] 0.59 [0.22, 1.60] 0.59 [0.23, 1.60] 0.61 [0.44, 1.37] 0.73 [0.55, 0.95] 6 0.75 [0.59, 0.95] 6 0.75 [0.59, 0.95] 6 0% Odds Ratio H, Random, 95% CI 0.41 [0.15, 1.08] 0.41 [0.15, 1.08] 0.41 [0.15, 1.08] 0.41 [0.45, 1.37] 0.65 [0.35, 1.23] 1%	0.01 0.1 10 100 Favours [experimental] Favours [control] 100 0dds Ratio M-H, Random, 95% Cl 0.01 0.1 10 100 Favours [experimental] Favours [control] 100 0dds Ratio M-H, Random, 95% Cl 0.01 M-H, Random, 95% Cl
Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect Test for overall effect Test for overall effect Araujo 2016 Foltys 2011 Han2016 Kim2012 Kim2012 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> + Test for overall effect Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> + Test for overall effect Test for overall effect Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Subtotal (95% CI)	$\begin{array}{c} 1 = 0.03 \ (F=0.03) \ (F=0$	829           166         -, df = 9 (P =           6)         -, df = 9 (P =           18, df = 1 (P         -           wents         Total           8         36           22         96           27         114           25         109           133         . df = 4 (P =           3)         1           1         34           32         186           5         55           4         11           42         . df = 3 (P =           8)         3           770         1275           175         . df = 1 (P           100         56           . df = 1 (P =           9)         96           27         114           29         96           210         56           . df = 1 (P =           9)         3           3         34           8         55           4         11           100         3	100.0% 0.98); $l^2 = 03$ $= 0.67$ ), $l^2 = 0.58$ ; 20.5% 13.2% 27.5% 0.98); $l^2 = 0.9$ 0.7% 19.3% 4.2% 1.5% 25.7% 0.74); $l^2 = 0.9$ 100.0% 0.71), $l^2 = 0.9$ 100.0% 0.99); $l^2 = 0.9$ 100.0% 0.99); $l^2 = 0.9$ 100.0% 0.92); $l^2 = 0.9$ 100.0% 1.5% 2.5% 0.92); $l^2 = 0.9$ 100.0% 1.5% 2.5% 0.92); $l^2 = 0.9$ 100.0% 1.5% 2.5% 0.92); $l^2 = 0.9$ 100.0% 0.92); $l^2 = 0.9$ 10.3% 2.9% 0.92); $l^2 = 0.9$ 10.3% 2.9% 0.92); $l^2 = 0.9$ 10.3% 2.9% 0.22); $l^2 = 3.4$ 8.8% 14.3% 2.7.9%	0.79 [0.62, 1.01] 6 0X Odds Ratio H, Random, 95X CI 0.69 [0.27, 1.72] 0.59 [0.22, 1.60] 0.69 [0.27, 1.72] 0.59 [0.22, 1.60] 0.61 [0.48, 1.37] 0.71 [0.35, 1.28] 0.74 [0.47, 1.81] 0.74 [0.47, 1.81] 0.74 [0.47, 1.81] 0.74 [0.47, 1.81] 0.74 [0.47, 1.81] 0.75 [0.59, 0.96] 6 0X Odds Ratio H, Random, 95X CI 0.81 [0.48, 1.37] 0.65 [0.35, 1.23] % 1.23 [0.33, 4.60] 0.38 [0.14, 1.08] 0.35 [0.05, 2.72] 0.36 [0.52, 1.22]	0.01 0.1 Favours [experimental] Favours [control] 00dds Ratio M-H, Random, 95% Cl 0.01 0.1 1 10 100 Favours [experimental] Favours [control]
Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect Test for overall effect Test for overall effect Araujo 2016 Foltys 2011 Han2016 Kim2012 Kwon 2021 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> + Test for overall effect Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> + Test for overall effect Test for overall effect Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Subtotal (95% CI) Total events	$\begin{array}{c} 1 = 0.03 \ (F=0.03) \ (F=0$	829           166           (df = 9 (P)           6)           18, df = 1 (P)           non-IBSA           wents Total           8           133           .df = 4 (P = 3)           1           133           .df = 4 (P = 3)           1           42           .df = 3 (P = 8)           7770           1275           .df = 3 (P = 8)           .df = 1 (P)           vents Total           29           .df = 1 (P = 9)           3           .df = 2 (P = 2)	<b>100.0%</b> <b>0.98</b> ); $l^2 = 03$ <b>0.98</b> ); $l^2 = 03$ <b>0.99</b> ); $l^2 = 03$ <b>100.0%</b> <b>0.71</b> ); $l^2 = 03$ <b>100.0%</b> <b>0.72</b> , $l^2 = 03$ <b>100.0%</b> <b>0.71</b> ); $l^2 = 03$ <b>100.0%</b> <b>0.72</b> , $l^2 = 03$ <b>100.0%</b> <b>0.72</b> , $l^2 = 03$ <b>100.0%</b> <b>0.71</b> , $l^2 = 03$ <b>100.0%</b> <b>0.72</b> , $l^2 = 03$ <b>100.0%</b> <b>0.72</b> , $l^2 = 03$ <b>100.0%</b> <b>0.72</b> , $l^2 = 03$ <b>0.71</b> , $l^2 = 34$ <b>0.88%</b> <b>1.4.3%</b> <b>2.7.1%</b> <b>0.34</b> ); $l^2 = 63$	0.79 [0.62, 1.01] 6 0X Odds Ratio H, Random, 95X CI 0.69 [0.27, 1.72] 0.59 [0.22, 1.60] 0.69 [0.27, 1.72] 0.79 [0.45, 1.37] 0.71 [0.47, 1.87] 0.74 [0.47, 1.87] 0.74 [0.47, 1.87] 0.74 [0.47, 1.87] 0.74 [0.47, 1.87] 0.74 [0.47, 1.87] 0.75 [0.59, 0.96] 6 0X Odds Ratio H, Random, 95X CI 0.41 [0.15, 1.08] 6 0.41 [0.15, 1.03] 6 0.41 [0.15, 1.03] 6 0.41 [0.15, 1.03] 6 0.41 [0.15, 1.23] 6 0.41 [0.15, 1.23] 6 0.41 [0.15, 1.23] 6 0.41 [0.15, 1.23] 6 0.41 [0.15, 1.23] 7 0.45 [0.35, 1.23] 7 1.23 [0.33, 4.60] 0.38 [0.14, 1.08] 0.35 [0.25, 2.72] 6	0.01 0.1 Favours [experimental] Favours [control] 00dds Ratio M-H, Random, 95% Cl 0.01 0.1 1 10 100 Favours [experimental] Favours [control]
Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect Test for overall effect Test for overall effect Test for overall effect Tast for overall effect 1.3.1 LDFs Araujo 2016 Foltys 2011 Han2016 Kim2012 Kim2012 2018 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> + Test for overall effect Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> + Test for overall effect Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> + Test for overall effect Test for overall effect 1.4.2 non-LDFs Nutu 2021 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> + Test for overall effect 1.4.2 non-LDFs Foltys 2011 Han2016 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> + Test for overall effect 1.4.2 non-LDFs	$\begin{array}{c} 1 = 0.01 (-0.01) (-0.01$	829           166           , df = 9 (P =           6)           18, df = 1 (P           wents Total           8           22           96           27           114           25           109           133           , df = 4 (P =           3)           1           42           464           32           133           , df = 4 (P =           3)           1           42           42           43           286           5           411           22           24, df = 1 (P           99           27           214, df = 1 (P =           99           3           , df = 1 (P =           99           3           , df = 1 (P =           3           3           4           1000           56           , df = 2 (P =           3      , df = 2 (P =      , df = 2 (P =	$\begin{array}{r} \textbf{100.0\%} \\ \textbf{0.98}; \ l^2 = 0.9\\ \textbf{0.98}; \ l^2 = 0.7; \ l^2 = 0.67; \ l^2 = 0.67; \ l^2 = 0.67; \ l^2 = 0.58; \ l^2 = 0.98; \ l^2 = 0.99; \ l^2 = 0.74; \ l^2 = 0$	0.79 [0.62, 1.01] Colds Ratio H, Random, 95X CI 0.69 [0.27, 1.72] 0.59 [0.22, 1.60] 0.69 [0.27, 1.72] 0.59 [0.22, 1.60] 0.61 [0.48, 1.37] 0.71 [0.35, 1.28] 0.74 [0.47, 1.28] 0.74 [0.47, 1.28] 0.74 [0.47, 1.28] 0.74 [0.47, 1.28] 0.75 [0.59, 0.96] 4 0.44 [0.03, 7.25] 0.39 [0.54, 1.59] 0.65 [0.20, 2.08] 0.55 [0.20, 2.21] 0.55 [0.20, 2.21	0.01 0.1 Favours [experimental] Favours [control] 00dds Ratio M-H, Random, 95% Cl 0.01 0.1 1 10 100 Favours [experimental] Favours [control] 00ds Ratio M-H, Random, 95% Cl
Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect Test for overall effect Test for overall effect 1.3.1 LDFs Araujo 2016 Foltys 2011 Han2016 Kim2012 Kwon 2021 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> a Test for overall effect Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> a Test for overall effect Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> a Test for overall effect Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> a Test for overall effect Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> a Test for overall effect Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> a Test for overall effect Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> a Test for overall effect Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> a Test for overall effect Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> a Test for overall effect 1.42 non-LDFs Heterogeneity: Tau <sup>2</sup> a Test for overall effect Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> a Test for overall effect 1.42 non-LDFs Heterogeneity: Tau <sup>2</sup> a Test for overall effect 1.52 non-LDFs Heterogeneity: Tau <sup>2</sup> a Test for overall effect 1.52 non-LDFs Heterogeneity: Tau <sup>2</sup> a Test for overall effect Total (95% CI) Total events	$\begin{array}{c} 121\\ 199\\ 1221\\ 199\\ 0.00; Ch^2 = 2.34\\ 200; Ch^2 = 2.34\\ 200; Ch^2 = 2.09\\ 122\\ 6\\ 122\\ 6\\ 122\\ 122\\ 6\\ 122\\ 122\\$	829           166           , df = 9 (P =           60           18, df = 1 (P           wents Total           8           22           96           27           114           25           109           133           , df = 4 (P =           3)           1           1           32           464           32           467           32           66           5           4           286           53           4           42           710           175           6f = 3 (P =           20           14, df = 1 (P           90           33           41           100           114           29           616           27           33           41           100           150           41           100      10	$\begin{array}{r} \textbf{100.0\%} \\ \textbf{0.98}; \ l^2 = 0.9\\ \textbf{0.98}; \ l^2 = 0.7; \ l^2 = 0.9; \ l^2 = 0.7; \ l^2 =$	0.79 [0.62, 1.01] Colored Statio H, Random, 95X CI 0.669 [0.27, 1.72] 0.59 [0.22, 1.60] 0.61 [0.48, 1.37] 0.70 [0.25, 0.96] 0.41 [0.48, 1.37] 0.73 [0.55, 0.96] 0.41 [0.04, 1.37] 0.73 [0.55, 0.96] 0.41 [0.04, 1.37] 0.73 [0.55, 0.96] 0.41 [0.04, 1.03] 0.45 [0.20, 2.04] 0.45 [0.44, 0.97] 0.41 [0.15, 1.08] 0.41 [0.15, 1.123] 1.23 [0.33, 4.60] 0.33 [0.05, 1.23] 1.23 [0.33, 4.60] 0.35 [0.25, 2.47] 0.36 [0.25, 1.22] 1.23 [0.35, 1.22] 1.23 [0.35, 1.23] 1.23 [0.35, 1.	0.01 0.1 Favours [experimental] Favours [control] 00dds Ratio M-H, Random, 95% CI 0.01 0.1 Favours [experimental] Favours [control] 00ds Ratio M-H, Random, 95% CI
Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Test for overall effect Test for subgroup dif C I.J.1 LDFs Araujo 2016 Foltys 2011 Han2016 Kim2012 Kim2012 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect I.J.F Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> - Test for overall effect Total events	$\begin{array}{c} 121\\ 199\\ 0.00; Ch^2 = 2.34\\ 2 = 1.90 \ P = 0.0\\ \hline \mbox{ferences: Chl^2 = 0.0}\\ \hline \mbox{ferences: Chl^2 = 0.0}\\ \hline \mbox{ferences: Chl^2 = 0.122}\\ 6 & 40\\ 57 & 283\\ 20 & 121\\ 72 & 220\\ 786\\ 177\\ 2 & 200; Chl^2 = 0.43\\ z & 2.124 \ (P = 0.0)\\ \hline for a line line line line line line line line$	$\begin{array}{c} 829\\ 166\\ , df = 9 (P \\ 6)\\ 18, df = 1 (P \\ 19, df = 3 \\ 27 \\ 114\\ 25 \\ 109\\ 133\\ . df = 4 (P = 3 \\ 133\\ . df = 4 (P = 3 \\ 133\\ . df = 4 (P = 3 \\ 134\\ . df = 3 (P = 6 \\ 134\\ . df = 3 (P = 6 \\ 114\\ . df = 1 (P \\ 114\\ . df = 1 (P \\ 19 \\ . df = 2 (P = 4 \\ 100\\ . df = 4 (P = 3 \\ 100\\ . df = 4 (P = 3 \\ 100\\ . df = 4 (P = 3 \\ 100\\ . df = 4 (P = 3 \\ 100\\ . df = 4 (P = 3 \\ 100\\ . df = 4 (P = 3 \\ 100\\ . df = 4 (P = 3 \\ 100\\ . df = 4 (P = 3 \\ 100\\ . df = 4 (P = 3 \\ 114\\ . df = 4 (P = 3 \\ . df = 3 $	100.0% 0.98); $l^2 = 03$ $= 0.677$ , $l^2 = 03$ Weight M- 6.7% 5.8% 20.5% 20.5% 13.2% 74.3% $0.98$ ); $l^2 = 03$ 0.7% 19.3% 4.2% 15.5% $0.98$ ); $l^2 = 03$ 0.7% 19.3% 4.2% 15.5% $0.74$ ); $l^2 = 03$ 100.0% $0.99$ ); $l^2 = 03$ 100.0% $0.71$ ), $l^2 = 03$ 100.0% $0.71$ ), $l^2 = 34$ 8.8% 14.3% 2.0% $0.34$ ); $l^2 = 63$ 100.0% $0.42$ ); $l^2 = 03$	0.79 [0.62, 1.01] Colds Ratio H, Random, 95X CI 0.69 [0.27, 1.72] 0.59 [0.22, 1.60] 0.61 [0.48, 1.37] 0.73 [0.55, 0.96] 4 0.41 [0.03, 7.25] 0.74 [0.47, 103, 1.28] 0.74 [0.47, 103, 1.28] 0.74 [0.47, 103, 1.28] 0.75 [0.59, 0.95] 4 0.75 [0.59, 0.95] 4 0.75 [0.59, 0.95] 4 0.41 [0.15, 1.08] 0.41 [0.15, 1.08] 0.41 [0.15, 1.08] 0.41 [0.15, 1.08] 0.41 [0.15, 1.123] 4 1.23 [0.33, 4.60] 0.35 [0.24, 2.07] 4 1.23 [0.33, 4.60] 0.35 [0.24, 2.07] 4 0.55 [0.44, 0.97] 4	0.01 0.1 Favours [experimental] Favours [control] 00dds Ratio M-H, Random, 95% CI 0.01 0.1 Favours [experimental] Favours [control] 00ds Ratio M-H, Random, 95% CI 00ds Ratio M-H, Random, 95% CI 00ds Ratio 00ds Ratio

08

A Study or Subgroup	IBSA Events	Total	non-ll Events	BSA Total	Weight	Odds Ratio M–H, Random, 95% Cl	Odds Ratio M-H, Random, 95% Cl
Araujo 2016	88	122	28	36	16.1%	0.74 [0.31, 1.78]	
Kwon 2021	205	220	115	129	21.5%	1.66 [0.78, 3.57]	
Subtotal (95% CI)		342		165	37.6%	1.14 [0.52, 2.53]	-
Total events	293 - 0 15: CH	$1^{2} - 1$	143 86 df -	1 (P -	0 17)- 12 -	- 46%	
Test for overall effect	z = 0.13, cr	B (P = 0)	).74)	I (r =	0.17),1 -	- 40/8	
152 non-I DEs							
Akbulut2013	17	24	46	59	10.8%	0.69 [0.23, 2.01]	
Ivanics2021	73	76	33	34	2.4%	0.74 [0.07, 7.36]	
Nutu 2021	168	192	170	186	28.0%	0.66 [0.34, 1.28]	
Pinto 2021	103	122	29	34	11.0%	0.93 [0.32, 2.72]	
Subtotal (95% CI)	120	545	50	368	62.4%	0.77 [0.49, 1.20]	•
Total events	481		328				
Heterogeneity: Tau <sup>2</sup> =	= 0.00; Ch	$ni^2 = 0$	.76, df =	4 (P =	0.94); l <sup>2</sup> =	- 0%	
lest for overall effect	z = 1.15	P = 0	).25)				
Total (95% CI)		887		533	100.0%	0.90 [0.63, 1.28]	◆
Total events	774	.2 .	471	c /n	0.000 12		
Heterogeneity: Tau" =	= 0.00; Cr	$11^{-} = 3.$ 7 (P - (	.91, df =	6 (P =	0.69); 1* =	= 0%	0.01 0.1 1 10 100
Test for subgroup dif	ferences:	Chi <sup>2</sup> =	0.73, df	= 1 (P	= 0.39), I	$^{2} = 0\%$	Favours [experimental] Favours [control]
в	IBSA		non-II	BSA		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
1.6.1 LDFs						0.07 /0 /0 0 0 0	
Araujo 2016 Kwon 2021	84	220	25	120	12.7%	0.97 [0.43, 2.18]	
Subtotal (95% CI)	105	342	52	165	35.3%	1.49 [0.75, 2.97]	• • • • • • • • • • • • • • • • • • •
Total events	267		117				
Heterogeneity: Tau <sup>2</sup> =	= 0.14; Ch	$1i^2 = 2$	.14, df =	1 (P =	0.14); l <sup>2</sup> =	= 53%	
lest for overall effect	Z = 1.14	f (P = (	).26)				
1.6.2 non-LDFs							
Akbulut2013	15	24	35	59	9.4%	1.14 [0.43, 3.03]	
Nutu 2021	136	192	142	186	25 7%	0.72 [0.18, 2.85]	
Pinto 2021	93	122	24	34	11.8%	1.34 [0.57, 3.12]	
Sutton 2021	111	131	44	55	12.5%	1.39 [0.61, 3.13]	
Subtotal (95% CI)	422	545	376	368	64.7%	0.95 [0.68, 1.32]	•
Heterogeneity: Tau <sup>2</sup> =	= 0.00: Cł	$1i^2 = 2$	.74. df =	4 (P =	0.60): 1 <sup>2</sup> =	- 0%	
Test for overall effect	z = 0.31	L (P = 0	0.76)				
Total (95% CI)		887		533	100.0%	1.16 [0.83, 1.62]	•
Total events	689		393				
Heterogeneity: Tau <sup>2</sup> =	= 0.06; Ch	$1i^2 = 8$	.47, df =	6 (P =	0.21); I <sup>2</sup> =	= 29%	0.01 0.1 1 10 100
Test for subgroup dif	ferences:	$Chi^2 = 0$	1.34, df	= 1 (P	= 0.25), I	<sup>2</sup> = 25.6%	Favours [experimental] Favours [control]
С	IBSA		non-II	BSA		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Araujo 2016	74	122	24	36	11.7%	0.77 [0.35, 1.69]	
Foltys 2011	24	40	55	96	12.5%	1.12 [0.53, 2.37]	
Kwon 2021	173	220	86	129	22.2%	1.84 [1.13, 3.00]	
Total events	271	302	165	201	-0.4%	1.20 [0.74, 2.12]	
Heterogeneity: Tau <sup>2</sup> =	= 0.10; Cł	1i <sup>2</sup> = 3.	.76, df =	2 (P =	0.15); l <sup>2</sup> =	= 47%	
Test for overall effect	z = 0.85	5 (P = 0	).39)				
1.7.2 non-LDFs							
Ivanics2021	63	76	30	34	5.7%	0.65 [0.19, 2.15]	
Nutu 2021 Pinto 2021	123	192	130	186	25.5%	0.77 [0.50, 1.18]	
Sutton 2021	106	131	23 44	55	11.5%	1.06 [0.48, 2.34]	
Subtotal (95% CI)		521		309	53.6%	0.84 [0.60, 1.17]	◆
Total events	375 = 0.00: CH	ni² = 0	227 90, df =	3 (P =	0.83): I <sup>2</sup> =	= 0%	
ricleiouelleite ia	: Z = 1.04	4 (P = 0	0.30)		//		
Test for overall effect				E 70	100.0%	1 04 [0 76 1 40]	<b>▲</b>
Test for overall effect Total (95% CI)		903		370	100.076	1.04 [0.70, 1.40]	•
Test for overall effect Total (95% CI) Total events	646	903	392	570	100.0%	1.04 [0.70, 1.40]	, , T
Test for overall effect Total (95% Cl) Total events Heterogeneity: Tau <sup>2</sup> =	646 = 0.05; Ch	903 $ni^2 = 8$	392 .38, df =	6 (P =	0.21); l <sup>2</sup> =	= 28%	0.01 0.1 1 10 100

10.3389/fonc.2022.985281

patients with cancer (15). Furthermore, a rencent study has demonstrated the effectiveness of IBSA in reducing the need for ABT for LT (41). A sizable prospective analysis that was conducted confirmed the cost effectiveness of IBSA. With the use of autologous transfusion over the study period, a cost saving of \$188618 United States dollars was achieved (42). In a multicenter research encompassing more than 33000 individuals, the risk of side effects associated with the usage of IBSA was estimated to range from 0% to 0.006% (11). Even though we need more evidence with large-sample size randomized control studies, those studies suggest that we should reduce the use of ABT.

Subgroup analysis was performed to determine whether results were differed due to the use of LDFs. LDFs were added to IBSA in the 1990s to increase the safety of the procedure (43). But it is still debatable whether LDFs completely decrease the risk of tumor cell metastasis. Several reports have demonstrated that LDFs are effective at eliminating tumor cells *in vitro* and vivo studies (39, 44, 45). However, there have been few reports using HCC cells. Unless there were large cell loads, according to Gwak's experimental results, LDF could filter HCC cells *in vitro* (46). And LDFs incorporated into cell salvage circuits have shown to effectively remove malignant cells when used during LT of patients with nonruptured hepatocellular tumors (16). Those studies support the hypothesis that tumor cells could be efficiently removed during collection, processing, and leukocyte filtration.

Six studies included in this meta-analysis attached LDFs to IBSA, in the subgroup analysis, IBSA-group has a low 5-year RR than non-IBSA group with the use of LDFs. This might be as a result of ABT's effect on immune function of patients with tumors. Besides 5-year RR outcome, non-LDFs-using group had similar results as the LDFs group. The above studies are insufficient to explain the adverse effects of the presence of tumor cells on clinical prognosis and to demonstrate negative effects associated with the use of IBSA. Some organizations, including the National Institute of Clinical Excellence, the Association of Anaesthetists of Great Britain and Ireland and the American College of Obstetricians and Gynecologists have developed guidelines to support the use of IBSA or in combination with LDFs in cancer surgery (14, 47-49). The findings in this study imply that using LDFs in combination may be a preferable way.

To our knowledge, a meta-analysis included eleven studies suggests that cancer recurrence after the use of IBSA is not inferior to traditional intraoperative allogeneic transfusion, with an odds ratio of 0.65 (95% CI, 0.43-0.98; P = 0.0391). But the included studies of this meta-analysis ranged from different cancer types, only three studies involved patients with hepatocellular carcinoma (50). In addition, another metaanalysis included 9 studies demonstrated that IBSA did not increase the tumor recurrence rate and had comparable survival outcomes with ABT. In the subgroup analysis of five studies for liver cancer surgery, IBSA did not increase the mortality risk with long-term follow-up for patients with hepatocellular carcinoma (51). The results presented above are approximately consistent with those of this meta-analysis, indicating that IBSA is not inferior to ABT and may even be better than ABT. In comparison, this review included 12 studies and provided the first comprehensive meta-analysis of effect of IBSA on clinical prognosis after LT for HCC, due to the lack of data, this analysis mainly focused on the clinical prognosis of IBSA. Predesigned subgroup analyses were conducted to evaluate whether the results were different with the use of LDFs. Multiple methods were adopted for sensitivity analyses, funnel plot and Egger regression test were used to estimate publication bias, which demonstrated the validity and robustness of the meta-analysis.

Several limitations of our study should be mentioned. First, the included studies were retrospective research and selection bias should not be ignored, since no RCT research on this question has been found after searching the databases. Well-designed, randomized, controlled, prospective trials are urgently required to clarify the existing concerns. Second, we only included English language studies due to the constraints of translating foreign language studies. Third, the included studies did not explore the use of allogeneic blood products, which may affect survival outcomes and prognosis due to their impact on immunity. Moreover, although significant heterogeneity was not found, patients' characteristics varied across included studies. Only part of included studies use a propensity score to control for the effect of confounding and address selection bias, more detailed subgroup analyses were difficult to conduct, because of multiple outcomes and insufficient studies.

# Conclusion

These 12 studies represent the best reliable evidence to date. This meta-analysis may at least indicate that intraoperative blood salvage autotransfusion provided comparable survival outcomes relative to allogeneic blood transfusion and did not increase the tumor recurrence for hepatocellular carcinoma patients after liver transplantation. A reappraisal of the appropriate strategy for blood management during liver transplantation is warranted. High quality researches are required in the future to provide more sufficient evidence.

# Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

# Author contributions

ZW developed the initial idea for this study. SL and KY developed and revised the search strategy. MS and ML finished the study design. KY and KL carried out data extraction and assessment of risk of bias. ZW, SL and YJ contributed to the original draft. DL and KL and were responsible for the revision of the draft. All of the authors approved the final work prior to submission ZW, SL and YJ have contributed equally to this work. All authors contributed to the article and approved the submitted version.

# Acknowledgments

The authors thank all the authors of the original studies included in this meta-analysis.

# **Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

# Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

# Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/ fonc.2022.985281/full#supplementary-material

#### SUPPLEMENTARY FIGURE 1

Meta-analysis forest plot of the overall survival after sensitivity analysis. (A), 1-year OS; (B), 3-year OS; (C), 5-year OS.

#### SUPPLEMENTARY FIGURE 2

Funnel plot of publication bias test for RR outcomes. Upper left, 1-year RR; Upper right, 3-year RR; Lower left, 5-year RR; Lower right, 7-year RR.

#### SUPPLEMENTARY FIGURE 3

Funnel plot of publication bias test for OS outcomes. Left, 1-year OS; Middle, 3-year OS; Right, 5-year OS.

# References

1. Sugawara Y, Hibi T. Surgical treatment of hepatocellular carcinoma. *Biosci Trends* (2021) 15(3):138–41. doi: 10.5582/bst.2021.01094

2. European Association For The Study Of The Liver and European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol* (2012) 56 (4):908–43. doi: 10.1016/j.jhep.2011.12.001

3. Wiesner RH, Freeman RB, Mulligan DC. Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy. *Gastroenterology* (2004) 127:S261-7. doi: 10.1053/j.gastro.2004.09.040

4. Cleland S, Corredor C, Ye JJ, Srinivas C, McCluskey SA. Massive haemorrhage in liver transplantation: Consequences, prediction and management. *World J Transplant* (2016) 6(2):291-305. doi: 10.5500/wjt.v6.i2.291

5. Feltracco P, Brezzi M, Barbieri S, Galligioni H, Milevoj M, Carollo C, et al. Blood loss, predictors of bleeding, transfusion practice and strategies of blood cell salvaging during liver transplantation. *World J Hepatol* (2013) 5(1):1–15. doi: 10.4254/wjh.v5.i1.1

6. Liu L, Wang Z, Jiang S, Shao B, Liu J, Zhang S, et al. Perioperative allogenenic blood transfusion is associated with worse clinical outcomes for hepatocellular carcinoma: a meta-analysis. *PloS One* (2013) 8(5):e64261. doi: 10.1371/journal.pone.0064261

7. Feltracco P, Michieletto E, Barbieri S, Serra E, Rizzi S, Salvaterra F, et al. Microbiologic contamination of intraoperative blood salvaged during liver transplantation. *Transplant Proc* (2007) 39(6):1889–91. doi: 10.1016/j.transproceed.2007.05.005

8. Gong Y, Tang Y, Xue Y, Chen L. Impact of intraoperative allogenic and autologous transfusion on immune function and prognosis in patients with hepatocellular carcinoma. *Med (Baltimore)* (2020) 99(41):e22568. doi: 10.1097/MD.0000000022568

9. Hill GE, Frawley WH, Griffith KE, Forestner JE, Minei JP. Allogeneic blood transfusion increases the risk of postoperative bacterial infection: a meta-analysis. J Trauma (2003) 54(5):908–14. doi: 10.1097/01.TA.0000022460.21283.53

10. Elmalky M, Yasin N, Rodrigues-Pinto R, Stephenson J, Carroll C, Smurthwaite G, et al. The safety, efficacy, and cost-effectiveness of intraoperative cell salvage in metastatic spine tumor surgery. *Spine J* (2017) 17(7):977–82. doi: 10.1016/j.spinee.2017.03.004

11. DeAndrade D, Waters JH, Triulzi DJ, Alarcon L, Wisniewski MK, Dyga R, et al. Very low rate of patient-related adverse events associated with the use of intraoperative cell salvage. *Transfusion* (2016) 56(11):2768–72. doi: 10.1111/trf.13791

12. Fahrner R, Dondorf F, Ardelt M, Dittmar Y, Settmacher U, Rauchfuß F. Liver transplantation for hepatocellular carcinoma - factors influencing outcome and disease-free survival. *World J Gastroenterol* (2015) 21(42):12071–82. doi: 10.3748/wjg.v21.i42.12071

13. Trudeau JD, Waters T, Chipperfield K. Should intraoperative cell-salvaged blood be used in patients with suspected or known malignancy? *Can J Anaesth* (2012) 59(11):1058–70. doi: 10.1007/s12630-012-9781-x

14. Foltys D, Zimmermann T, Heise M, Kaths M, Lautem A, Wisser G, et al. Liver transplantation for hepatocellular carcinoma-is there a risk of recurrence caused by intraoperative blood salvage autotransfusion? *Eur Surg Res* (2011) 47 (3):182–7. doi: 10.1159/000330746

15. Kozek-Langenecker SA, Ahmed AB, Afshari A, Albaladejo P, Aldecoa C, Barauskas G, et al. Management of severe perioperative bleeding: guidelines from the European society of anaesthesiology: First update 2016. *Eur J Anaesthesiol* (2017) 34(6):332–95. doi: 10.1097/EJA.00000000000630

16. Pinto MA, Chedid MF, Sekine L, Schmidt AP, Capra RP, Prediger C, et al. Intraoperative cell salvage with autologous transfusion in liver transplantation. *World J Gastrointest Surg* (2019) 11(1):11–8. doi: 10.4240/wjgs.v11.i1.11 17. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Syst Rev* (2021) 10(1):89. doi: 10.1186/s13643-021-01626-4

18. Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the cochrane handbook for systematic reviews of interventions. *Cochrane Database Syst Rev* (2019) 10:ED000142. doi: 10.1002/14651858.ED000142

19. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The cochrane collaboration's tool for assessing risk of bias in randomised trials. *BMJ* (2011) 343:d5928. doi: 10.1136/bmj.d5928

20. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol* (2010) 25(9):603–5. doi: 10.1007/s10654-010-9491-z

21. Bruix J, Sherman MAmerican Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. *Hepatology* (2011) 53 (3):1020–2. doi: 10.1002/hep.24199

22. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med Res Methodol* (2014) 14:135. doi: 10.1186/1471-2288-14-135

23. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med (2002) 21(11):1539-58. doi: 10.1002/sim.1186

24. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* (1997) 315(7109):629–34. doi: 10.1136/ bmj.315.7109.629

25. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. *BMJ* (2011) 343:d4002. doi: 10.1136/bmj.d4002

26. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials. the CONSORT statement. *JAMA* (1996) 276(8):637–9. doi: 10.1001/jama.276.8.637

27. Akbulut S, Kayaalp C, Yilmaz M, Ince V, Ozgor D, Karabulut K, et al. Effect of autotransfusion system on tumor recurrence and survival in hepatocellular carcinoma patients. *World J Gastroenterol* (2013) 19(10):1625–31. doi: 10.3748/wjg.v19.i10.1625

28. Araujo RL, Pantanali CA, Haddad L, Rocha Filho JA, D'Albuquerque LA, Andraus W. Does autologous blood transfusion during liver transplantation for hepatocellular carcinoma increase risk of recurrence? *World J Gastrointest Surg* (2016) 8(2):161–8. doi: 10.4240/wjgs.v8.i2.161

29. Han S, Kim G, Ko JS, Sinn DH, Yang JD, Joh JW, et al. Safety of the use of blood salvage and autotransfusion during liver transplantation for hepatocellular carcinoma. *Ann Surg* (2016) 264(2):339–43. doi: 10.1097/SLA.000000000001486

30. Ivanics T, Shubert CR, Muaddi H, Claasen MPAW, Yoon P, Hansen BE, et al. Blood cell salvage and autotransfusion does not worsen oncologic outcomes following liver transplantation with incidental hepatocellular carcinoma: A propensity score-matched analysis. *Ann Surg Oncol* (2021) 28(11):6816–25. doi: 10.1245/s10434-021-09863-6

31. Kim JM, Kim GS, Joh JW, Suh KS, Park JB, Ko JS, et al. Long-term results for living donor liver transplant recipients with hepatocellular carcinoma using intraoperative blood salvage with leukocyte depletion filter. *Transpl Int* (2013) 26 (1):84–9. doi: 10.1111/tri.12001

32. Kwon JH, Han S, Kim D, Kuk JH, Cho H, Kim S, et al. Blood salvage and autotransfusion does not increase the risk of tumor recurrence after liver transplantation for advanced hepatocellular carcinoma. *Ann Surg* (2021). doi: 10.1097/SLA.000000000004866

33. Muscari F, Suc B, Vigouroux D, Duffas JP, Miqueres I, Mathieu A, et al. Blood salvage autotransfusion during transplantation for hepatocarcinoma: does it increase the risk of neoplastic recurrence? *Transpl Int* (2005) 18(11):1236–9. doi: 10.1111/j.1432-2277.2005.00207.x

34. Nutu OA, Sneiders D, Mirza D, Isaac J, Perera MTPR, Hartog H. Safety of intra-operative blood salvage during liver transplantation in patients with

hepatocellular carcinoma, a propensity score-matched survival analysis. *Transpl Int* (2021) 34(12):2887–94. doi: 10.1111/tri.14150

35. Pinto MA, Grezzana-Filho TJM, Chedid AD, Leipnitz I, Prediger JE, Alvares-da-Silva MR, et al. Impact of intraoperative blood salvage and autologous transfusion during liver transplantation for hepatocellular carcinoma. *Langenbecks Arch Surg* (2021) 406(1):67–74. doi: 10.1007/s00423-020-01997-7

36. Sutton TL, Pasko J, Kelly G, Maynard E, Connelly C, Orloff S, et al. Intraoperative autologous transfusion and oncologic outcomes in liver transplantation for hepatocellular carcinoma: a propensity matched analysis. *HPB (Oxford)* (2022) 24(3):379–85. doi: 10.1016/j.hpb.2021.06.433

37. Weller A, Seyfried T, Ahrens N, Baier-Kleinhenz L, Schlitt H, Peschel G, et al. Cell salvage during liver transplantation for hepatocellular carcinoma: A retrospective analysis of tumor recurrence following irradiation of the salvaged blood. *Transplant Proc* (2021) 53(5):1639–44. doi: 10.1016/j.transproceed. 2021.03.025

38. Zhai B, Sun XY. Controversy over the use of intraoperative blood salvage autotransfusion during liver transplantation for hepatocellular carcinoma patients. *World J Gastroenterol* (2013) 19(22):3371–4. doi: 10.3748/wjg.v19.i22.3371

39. Hansen E, Bechmann V, Altmeppen J. Intraoperative blood salvage in cancer surgery: safe and effective? *Transfus Apher Sci* (2002) 27(2):153-7. doi: 10.1016/s1473-0502(02)00037-x

40. Yaw PB, Sentany M, Link WJ, Wahle WM, GGlover JL. Tumor cells carried through autotransfusion. contraindication to intraoperative blood recovery? *JAMA* (1975) 231(5):490–1.

41. Massicotte L, Thibeault L, Beaulieu D, Roy JD, Roy A. Evaluation of cell salvage autotransfusion utility during liver transplantation. *HPB (Oxford)* (2007) 9 (1):52–7. doi: 10.1080/13651820601090596

42. Phillips SD, Maguire D, Deshpande R, Muiesan P, Bowles MJ, Rela M, et al. A prospective study investigating the cost effectiveness of intraoperative blood salvage during liver transplantation. *Transplantation* (2006) 81(4):536–40. doi: 10.1097/01.tp.0000199318.17013.c5

43. Edelman MJ, Potter P, Mahaffey KG, Frink R, Leidich RB. The potential for reintroduction of tumor cells during intraoperative blood salvage: reduction of risk with use of the RC-400 leukocyte depletion filter. *Urology* (1996) 47(2):179–81. doi: 10.1016/S0090-4295(99)80411-7

44. Futamura N, Nakanishi H, Hirose H, Nakamura S, Tatematsu M. The effect of storage on the survival of cancer cells in blood and efficient elimination of contaminating cancer cells by a leukocyte depletion filter. *Am Surg* (2005) 71 (7):585–90.

45. Frühauf NR, Dumpich O, Kaudel CP, Kasimir-Bauer S, Oldhafer KJ. Filtration of malignant cells: tumour cell depletion in an ex vivo model using a leukocyte adhesion filter. *Perfusion* (2001) 16 Suppl:51–5. doi: 10.1177/ 026765910101600i107

46. Gwak MS, Lee KW, Kim SY, Lee J, Joh JW, Kim SJ, et al. Can a leukocyte depletion filter (LDF) reduce the risk of reintroduction of hepatocellular carcinoma cells? *Liver Transpl* (2005) 11(3):331–5. doi: 10.1002/lt.20346

47. Catling S, Williams S, Freites O, Rees M, Davies C, Hopkins L. Use of a leucocyte filter to remove tumour cells from intra-operative cell salvage blood. *Anaesthesia* (2008) 63(12):1332–8. doi: 10.1111/j.1365-2044.2008.05637.x

48. Esper SA, Waters JH. Intra-operative cell salvage: a fresh look at the indications and contraindications. *Blood Transfus* (2011) 9(2):139-47. doi: 10.2450/2011.0081-10

49. Bouras I, Mingo O. Should cell salvage be used in oncological surgery? Br J Hosp Med (Lond) (2010) 71(1):57. doi: 10.12968/hmed.2010.71.1.45980

50. Waters JH, Yazer M, Chen YF, Kloke J. Blood salvage and cancer surgery: a meta-analysis of available studies. *Transfusion* (2012) 52(10):2167-73. doi: 10.1111/j.1537-2995.2011.03555.x

51. Wu WW, Zhang WY, Zhang WH, Yang L, Deng XQ, Ou MC, et al. Survival analysis of intraoperative blood salvage for patients with malignancy disease: A PRISMA-compliant systematic review and meta-analysis. *Med (Baltimore)* (2019) 98(27):e16040. doi: 10.1097/MD.00000000016040